WO2023247595A1 - Pyrazolopyrazine carboxamides et leurs utilisations comme inhibiteurs de pdgfr - Google Patents
Pyrazolopyrazine carboxamides et leurs utilisations comme inhibiteurs de pdgfr Download PDFInfo
- Publication number
- WO2023247595A1 WO2023247595A1 PCT/EP2023/066732 EP2023066732W WO2023247595A1 WO 2023247595 A1 WO2023247595 A1 WO 2023247595A1 EP 2023066732 W EP2023066732 W EP 2023066732W WO 2023247595 A1 WO2023247595 A1 WO 2023247595A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrazolo
- pyrazine
- carboxamide
- methyl
- pyrazol
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 6
- HBCLHTZZQPIVLB-UHFFFAOYSA-N 2H-pyrazolo[3,4-b]pyrazine-3-carboxamide Chemical class C1=CN=C2C(C(=O)N)=NNC2=N1 HBCLHTZZQPIVLB-UHFFFAOYSA-N 0.000 title 1
- 101150093908 PDGFRB gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 349
- 238000000034 method Methods 0.000 claims abstract description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- -1 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl Chemical group 0.000 claims description 1183
- 229910052757 nitrogen Inorganic materials 0.000 claims description 265
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 209
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 141
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 82
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 76
- 201000010099 disease Diseases 0.000 claims description 75
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 75
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 67
- 208000035475 disorder Diseases 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 66
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 62
- 125000004076 pyridyl group Chemical group 0.000 claims description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 125000004122 cyclic group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 15
- 125000003107 substituted aryl group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- LUMNJBXUQJNORG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrazine-3-carboxamide Chemical compound C1=CN=CC2=C(C(=O)N)C=NN21 LUMNJBXUQJNORG-UHFFFAOYSA-N 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 206010021143 Hypoxia Diseases 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000035977 Rare disease Diseases 0.000 claims description 4
- 238000000423 cell based assay Methods 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 210000001147 pulmonary artery Anatomy 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 description 211
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 171
- 239000007787 solid Substances 0.000 description 131
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 128
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 110
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 109
- 238000006243 chemical reaction Methods 0.000 description 96
- 230000015572 biosynthetic process Effects 0.000 description 89
- 229910001868 water Inorganic materials 0.000 description 89
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 238000003786 synthesis reaction Methods 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 84
- 239000000243 solution Substances 0.000 description 74
- 239000002904 solvent Substances 0.000 description 72
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- 239000011541 reaction mixture Substances 0.000 description 47
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- 239000003153 chemical reaction reagent Substances 0.000 description 41
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- 239000000543 intermediate Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 35
- 238000002953 preparative HPLC Methods 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 30
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 239000003921 oil Substances 0.000 description 27
- 235000014113 dietary fatty acids Nutrition 0.000 description 26
- 239000000194 fatty acid Substances 0.000 description 26
- 229930195729 fatty acid Natural products 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 26
- 239000000725 suspension Substances 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- 239000002585 base Substances 0.000 description 23
- 229910000024 caesium carbonate Inorganic materials 0.000 description 23
- 239000007858 starting material Substances 0.000 description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 239000002253 acid Substances 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 21
- 208000029523 Interstitial Lung disease Diseases 0.000 description 21
- 239000004094 surface-active agent Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 150000001721 carbon Chemical group 0.000 description 19
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 13
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 13
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 13
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000008878 coupling Effects 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- VISQRHAHDGYTJK-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxylic acid Chemical compound CN1N=CC(=C1)C=1N=CC=2N(C1)N=CC2C(=O)O VISQRHAHDGYTJK-UHFFFAOYSA-N 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- 239000007821 HATU Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 10
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 235000013772 propylene glycol Nutrition 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 9
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229930182558 Sterol Natural products 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 125000000168 pyrrolyl group Chemical group 0.000 description 9
- 150000003432 sterols Chemical class 0.000 description 9
- 235000003702 sterols Nutrition 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000001041 indolyl group Chemical group 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 125000001544 thienyl group Chemical group 0.000 description 8
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 7
- 229920000742 Cotton Polymers 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 125000000842 isoxazolyl group Chemical group 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 125000001425 triazolyl group Chemical group 0.000 description 7
- 229960000281 trometamol Drugs 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 6
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 125000003709 fluoroalkyl group Chemical group 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 6
- VLZLEPNAKIFDQJ-UHFFFAOYSA-N n-pyridin-2-ylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=N1 VLZLEPNAKIFDQJ-UHFFFAOYSA-N 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- 239000012264 purified product Substances 0.000 description 6
- 125000002098 pyridazinyl group Chemical group 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- NCADHSLPNSTDMJ-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(C(O)=O)C1 NCADHSLPNSTDMJ-UHFFFAOYSA-N 0.000 description 5
- RZPSBEGGSZWYAN-UHFFFAOYSA-N 6-methyl-5-nitropyridin-3-amine Chemical compound CC1=NC=C(N)C=C1[N+]([O-])=O RZPSBEGGSZWYAN-UHFFFAOYSA-N 0.000 description 5
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 229910004373 HOAc Inorganic materials 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 235000010216 calcium carbonate Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- DHAJBKCRNCFLMM-UHFFFAOYSA-N ethyl 6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxylate Chemical compound CCOC(=O)C1=C2C=NC(=CN2N=C1)C3=CN(N=C3)C DHAJBKCRNCFLMM-UHFFFAOYSA-N 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000000787 lecithin Chemical class 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- MNKCGUKVRJZKEQ-MIXQCLKLSA-N (1z,5z)-cycloocta-1,5-diene;iridium;methanol Chemical compound [Ir].[Ir].OC.OC.C\1C\C=C/CC\C=C/1.C\1C\C=C/CC\C=C/1 MNKCGUKVRJZKEQ-MIXQCLKLSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- CEBUOOAEYWDXFN-UHFFFAOYSA-N 1-phenyl-n-(1h-pyrazol-5-ylmethyl)methanamine Chemical compound C=1C=NNC=1CNCC1=CC=CC=C1 CEBUOOAEYWDXFN-UHFFFAOYSA-N 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- BXBHKXOTSRTJON-UHFFFAOYSA-N 2-(1,3-dibromopropan-2-yloxy)oxane Chemical compound BrCC(CBr)OC1CCCCO1 BXBHKXOTSRTJON-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- NPAXPTHCUCUHPT-UHFFFAOYSA-N 3,4,7,8-tetramethyl-1,10-phenanthroline Chemical compound CC1=CN=C2C3=NC=C(C)C(C)=C3C=CC2=C1C NPAXPTHCUCUHPT-UHFFFAOYSA-N 0.000 description 4
- JLPWVZVJLOAIRV-UHFFFAOYSA-N 3-amino-N-[2-(2,2-dimethylpyrrolidin-1-yl)ethyl]-4-fluorobenzamide Chemical compound CC1(C)N(CCNC(C(C=C2)=CC(N)=C2F)=O)CCC1 JLPWVZVJLOAIRV-UHFFFAOYSA-N 0.000 description 4
- GDSQTWDUCDSZEY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indazole Chemical compound C1CCCC2=C1C=NN2 GDSQTWDUCDSZEY-UHFFFAOYSA-N 0.000 description 4
- WOJOEHSQAVJXGC-UHFFFAOYSA-N 5-amino-N-[2-(2,2-dimethylpyrrolidin-1-yl)ethyl]-6-methylpyridine-3-carboxamide Chemical compound CC1(C)N(CCNC(C2=CN=C(C)C(N)=C2)=O)CCC1 WOJOEHSQAVJXGC-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- QXIGOXIYHSLNSE-UHFFFAOYSA-N CC1CNC(=O)c2c(I)cnn12 Chemical compound CC1CNC(=O)c2c(I)cnn12 QXIGOXIYHSLNSE-UHFFFAOYSA-N 0.000 description 4
- GUSJEBHKRWYAKJ-UHFFFAOYSA-N CCOC(=O)c1c(I)cnn1C(C)CNC(=O)OC(C)(C)C Chemical compound CCOC(=O)c1c(I)cnn1C(C)CNC(=O)OC(C)(C)C GUSJEBHKRWYAKJ-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 229910002666 PdCl2 Inorganic materials 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000000783 alginic acid Substances 0.000 description 4
- 229960001126 alginic acid Drugs 0.000 description 4
- 150000004781 alginic acids Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 125000005956 isoquinolyl group Chemical group 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229940070765 laurate Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000008117 stearic acid Chemical group 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- UGNJWDSVTJMOGR-UHFFFAOYSA-N tert-butyl 7-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate Chemical compound CC1CN(CC2=CC=NN12)C(=O)OC(C)(C)C UGNJWDSVTJMOGR-UHFFFAOYSA-N 0.000 description 4
- ZRAZMNJGRXNMOD-UHFFFAOYSA-N tert-butyl N-benzyl-N-(1H-pyrazol-5-ylmethyl)carbamate Chemical compound C(C1=CC=CC=C1)N(C(OC(C)(C)C)=O)CC1=NNC=C1 ZRAZMNJGRXNMOD-UHFFFAOYSA-N 0.000 description 4
- VWFNJRUKTFGZJN-UHFFFAOYSA-N tert-butyl n-(3-amino-4-fluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(F)C(N)=C1 VWFNJRUKTFGZJN-UHFFFAOYSA-N 0.000 description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 description 4
- 125000005306 thianaphthenyl group Chemical group 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical class CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 3
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZSHAGSDVWLLMSY-UHFFFAOYSA-N 2-(2,2-dimethylpyrrolidin-1-yl)ethanamine Chemical compound CC1(C)CCCN1CCN ZSHAGSDVWLLMSY-UHFFFAOYSA-N 0.000 description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 3
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 3
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 3
- IASRYLKZYZPWRV-UHFFFAOYSA-N 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine Chemical compound C1CCOC2=CC=NN21 IASRYLKZYZPWRV-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical class C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 229910020889 NaBH3 Inorganic materials 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical class CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- IELXBVQPSMCMKP-UHFFFAOYSA-N ethyl 2-(5-chloropyrazin-2-yl)acetate Chemical compound CCOC(=O)CC1=CN=C(Cl)C=N1 IELXBVQPSMCMKP-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 239000000174 gluconic acid Chemical group 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 125000005456 glyceride group Chemical class 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000002563 ionic surfactant Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 150000003899 tartaric acid esters Chemical class 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- WJTCHBVEUFDSIK-NWDGAFQWSA-N (2r,5s)-1-benzyl-2,5-dimethylpiperazine Chemical compound C[C@@H]1CN[C@@H](C)CN1CC1=CC=CC=C1 WJTCHBVEUFDSIK-NWDGAFQWSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 1,2-dimethoxyethane;hydrate Chemical compound O.COCCOC ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OEZPKXDBWNXBRE-UHFFFAOYSA-N 2,3-bis(2-hydroxyethoxy)propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(OCCO)COCCO OEZPKXDBWNXBRE-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- GDWKIRLZWQQMIE-QMMMGPOBSA-N 2-[(2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CC(O)=O GDWKIRLZWQQMIE-QMMMGPOBSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 2
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 description 2
- 108010038807 Oligopeptides Chemical class 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 2
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 208000021066 Pulmonary arterial hypertension associated with connective tissue disease Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000032594 Vascular Remodeling Diseases 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 2
- 208000018578 heart valve disease Diseases 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- SPAKMVQVTSVXES-UHFFFAOYSA-N methanol;oxolane;hydrate Chemical compound O.OC.C1CCOC1 SPAKMVQVTSVXES-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- YYZUSRORWSJGET-UHFFFAOYSA-N octanoic acid ethyl ester Natural products CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- 125000005961 oxazepanyl group Chemical group 0.000 description 2
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical class [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LQMMFVPUIVBYII-RXMQYKEDSA-N (2r)-2-methylmorpholine Chemical compound C[C@@H]1CNCCO1 LQMMFVPUIVBYII-RXMQYKEDSA-N 0.000 description 1
- JEQDSBVHLKBEIZ-REOHCLBHSA-N (2s)-2-chloropropanoyl chloride Chemical compound C[C@H](Cl)C(Cl)=O JEQDSBVHLKBEIZ-REOHCLBHSA-N 0.000 description 1
- MXKSXPYZNXUHEZ-SFYZADRCSA-N (2s,4r)-4-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C[C@@H]1C[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)C1 MXKSXPYZNXUHEZ-SFYZADRCSA-N 0.000 description 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- KIHQZLPHVZKELA-UHFFFAOYSA-N 1,3-dibromopropan-2-ol Chemical compound BrCC(O)CBr KIHQZLPHVZKELA-UHFFFAOYSA-N 0.000 description 1
- FBNAMBTYMSWTIB-UHFFFAOYSA-N 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 FBNAMBTYMSWTIB-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- IGPSPBNOEVKQBV-UHFFFAOYSA-N 1-(azetidin-3-yl)piperidine;dihydrochloride Chemical compound Cl.Cl.C1NCC1N1CCCCC1 IGPSPBNOEVKQBV-UHFFFAOYSA-N 0.000 description 1
- AOWCOHYBGYRYGE-UHFFFAOYSA-N 1-[2,3-bis(2-oxopropoxy)propoxy]propan-2-one Chemical compound CC(=O)COCC(OCC(C)=O)COCC(C)=O AOWCOHYBGYRYGE-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- CKPAOPWAVKSUPQ-UHFFFAOYSA-N 1-propan-2-ylpyrrolidin-1-ium-2-carboxylate Chemical compound CC(C)N1CCCC1C(O)=O CKPAOPWAVKSUPQ-UHFFFAOYSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- ICFGFAUMBISMLR-UHFFFAOYSA-N 1h-pyrazole-5-carbaldehyde Chemical compound O=CC=1C=CNN=1 ICFGFAUMBISMLR-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- PHODFIDDEBEGCS-UHFFFAOYSA-N 2,2-dimethylpyrrolidine Chemical compound CC1(C)CCCN1 PHODFIDDEBEGCS-UHFFFAOYSA-N 0.000 description 1
- YTORMSBGFMQNEO-UHFFFAOYSA-N 2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl octanoate;(3-hydroxy-2-octanoyloxypropyl) octanoate;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(=O)OCC(O)CO.CCCCCCCCCC(=O)OCC(O)CO.CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC YTORMSBGFMQNEO-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- UGDAWAQEKLURQI-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethanol;hydrate Chemical compound O.OCCOCCO UGDAWAQEKLURQI-UHFFFAOYSA-N 0.000 description 1
- CWLNLZLFEYXVDY-UHFFFAOYSA-N 2-(5-chloro-4-methoxy-6-methylpyrimidin-2-yl)oxypropanenitrile Chemical compound COC1=NC(OC(C)C#N)=NC(C)=C1Cl CWLNLZLFEYXVDY-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- PPPFYBPQAPISCT-UHFFFAOYSA-N 2-hydroxypropyl acetate Chemical compound CC(O)COC(C)=O PPPFYBPQAPISCT-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- HAEBOIOLDSOIGG-UHFFFAOYSA-N 2-pyrrolidin-1-ium-1-ylpropanoate Chemical compound OC(=O)C(C)N1CCCC1 HAEBOIOLDSOIGG-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- ZPOPPIQRQXFRNA-NYYWCZLTSA-N 3-[(E)-(carbamoylhydrazinylidene)methyl]-2-hydroxybenzoic acid Chemical compound NC(=O)N\N=C\c1cccc(C(O)=O)c1O ZPOPPIQRQXFRNA-NYYWCZLTSA-N 0.000 description 1
- HPKXYVYKZCJKIP-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane;hydrochloride Chemical compound Cl.C1CC2CCC1NC2 HPKXYVYKZCJKIP-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KCABEFWZFQEYNC-UHFFFAOYSA-N 3-thia-1-azabicyclo[3.1.1]heptane Chemical compound C1C2CN1CSC2 KCABEFWZFQEYNC-UHFFFAOYSA-N 0.000 description 1
- MRWWWZLJWNIEEJ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yloxy-1,3,2-dioxaborolane Chemical compound CC(C)OB1OC(C)(C)C(C)(C)O1 MRWWWZLJWNIEEJ-UHFFFAOYSA-N 0.000 description 1
- QGSMPWPXQRBVDP-UHFFFAOYSA-N 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-5-ol Chemical compound C1C(O)CCN2N=CC=C21 QGSMPWPXQRBVDP-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- BOJWTAQWPVBIPG-UHFFFAOYSA-N 4-fluoro-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 BOJWTAQWPVBIPG-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- KDQUXBVINRXSSD-UHFFFAOYSA-N 5-amino-6-methylpyridine-3-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)C=C1N KDQUXBVINRXSSD-UHFFFAOYSA-N 0.000 description 1
- FOMNEVDLMZUAJY-UHFFFAOYSA-N 5-azaspiro[3.4]octane Chemical compound C1CCC21NCCC2 FOMNEVDLMZUAJY-UHFFFAOYSA-N 0.000 description 1
- WGVHNCAJPFIFCR-UHFFFAOYSA-N 5-methyl-1,2-dihydropyrazol-3-one Chemical compound CC1=CC(O)=NN1 WGVHNCAJPFIFCR-UHFFFAOYSA-N 0.000 description 1
- MKKJTADNAAPSQP-UHFFFAOYSA-N 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyridin-2-one Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(=O)N1 MKKJTADNAAPSQP-UHFFFAOYSA-N 0.000 description 1
- GEVUGWURIMZLKE-UHFFFAOYSA-N 6-methyl-5-nitropyridine-3-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)C=C1[N+]([O-])=O GEVUGWURIMZLKE-UHFFFAOYSA-N 0.000 description 1
- SOIDQYXQSTZLHM-UHFFFAOYSA-N 6-oxa-1-azabicyclo[3.1.1]heptane Chemical compound C1N2OC1CCC2 SOIDQYXQSTZLHM-UHFFFAOYSA-N 0.000 description 1
- IFXJRUFJNGIPHJ-UHFFFAOYSA-N 7-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine Chemical compound CC1CNCC2=CC=NN12 IFXJRUFJNGIPHJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- JCSJWSJDIPIKHS-UHFFFAOYSA-N N-(5-amino-6-methylpyridin-3-yl)-2-(2,2-dimethylpyrrolidin-1-yl)acetamide Chemical compound CC1(C)N(CC(NC2=CC(N)=C(C)N=C2)=O)CCC1 JCSJWSJDIPIKHS-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Chemical class 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000021076 Pulmonary arterial hypertension associated with congenital heart disease Diseases 0.000 description 1
- 208000021068 Pulmonary arterial hypertension associated with portal hypertension Diseases 0.000 description 1
- 208000021083 Pulmonary arterial hypertension associated with schistosomiasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000038012 SFKs Human genes 0.000 description 1
- 108091008118 SFKs Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000001833 Succinylated monoglyceride Substances 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- GNVWVYIAQBJHGV-UHFFFAOYSA-N azetidin-3-ylmethanol Chemical compound OCC1CNC1 GNVWVYIAQBJHGV-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- GSCLMSFRWBPUSK-UHFFFAOYSA-N beta-Butyrolactone Chemical compound CC1CC(=O)O1 GSCLMSFRWBPUSK-UHFFFAOYSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- XYZUWOHEILWUID-UHFFFAOYSA-N bromomethylcyclopentane Chemical compound BrCC1CCCC1 XYZUWOHEILWUID-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical class CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 108700043024 cholylsarcosine Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-M ethanimidate Chemical compound CC([O-])=N DLFVBJFMPXGRIB-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RQDRTNYFCCJKAK-SREVYHEPSA-N ethyl (2z)-2-(3-chloro-1h-pyridazin-6-ylidene)-2-cyanoacetate Chemical compound CCOC(=O)C(\C#N)=C1/NN=C(Cl)C=C1 RQDRTNYFCCJKAK-SREVYHEPSA-N 0.000 description 1
- JVVOVNIIDBZSJC-UHFFFAOYSA-N ethyl 4-[2-(4-fluoroanilino)-2-oxoethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1CC(=O)NC1=CC=C(F)C=C1 JVVOVNIIDBZSJC-UHFFFAOYSA-N 0.000 description 1
- MOURTQXAPIMDJC-UHFFFAOYSA-N ethyl 4-iodo-1h-pyrazole-5-carboxylate Chemical compound CCOC(=O)C=1NN=CC=1I MOURTQXAPIMDJC-UHFFFAOYSA-N 0.000 description 1
- LKGZPPSZEDDGAG-UHFFFAOYSA-N ethyl 5-amino-6-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(C)C(N)=C1 LKGZPPSZEDDGAG-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229940037959 monooctanoin Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- IYRGXJIJGHOCFS-UHFFFAOYSA-N neocuproine Chemical compound C1=C(C)N=C2C3=NC(C)=CC=C3C=CC2=C1 IYRGXJIJGHOCFS-UHFFFAOYSA-N 0.000 description 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940077412 peg-12 laurate Drugs 0.000 description 1
- 229940008456 peg-32 oleate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001693 poly(ether-ester) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Chemical class 0.000 description 1
- 150000007519 polyprotic acids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- KDZOHLVVUNZUQC-UHFFFAOYSA-N pyrazolo[1,5-a]pyrazine-3-carboxylic acid Chemical compound C1=CN=CC2=C(C(=O)O)C=NN21 KDZOHLVVUNZUQC-UHFFFAOYSA-N 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019327 succinylated monoglyceride Nutrition 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- IPISOFJLWYBCAV-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 IPISOFJLWYBCAV-UHFFFAOYSA-N 0.000 description 1
- NUIGEPXSRGNKQX-UHFFFAOYSA-N tert-butyl N-(5-amino-6-methylpyridin-3-yl)carbamate Chemical compound Cc1ncc(NC(=O)OC(C)(C)C)cc1N NUIGEPXSRGNKQX-UHFFFAOYSA-N 0.000 description 1
- YNJCFDAODGKHAV-UHFFFAOYSA-N tert-butyl n-(2-hydroxypropyl)carbamate Chemical compound CC(O)CNC(=O)OC(C)(C)C YNJCFDAODGKHAV-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 150000003527 tetrahydropyrans Chemical class 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000006300 thietan-3-yl group Chemical group [H]C1([H])SC([H])([H])C1([H])* 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- GF growth factors
- GF bind to several different receptors that amplify the signal through activation of the specific receptor through phosphorylation, leading to confirmation changes increasing the affinity for ATP and the phosphorylation of downstream proteins leading to activation of several signaling cascades. Therefore, small changes in GF or the cognate receptors can significantly alter the local signaling and have dramatic effects on initiation and progression of many diseases.
- Platelet-derived growth factor (PDGF) is one of many GFs that regulate cell growth and division. PDGF exerts its biological responses via activation of two highly specific, transmembrane receptor tyrosine kinases, termed PDGFR ⁇ and PDGFR ⁇ , which can form three different dimeric receptors – ⁇ , ⁇ and ⁇ .
- receptors can interact with the different dimeric PDGF ligands (PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD and PDGF-AB) with different specificities and efficacies.
- the receptors are activated by ligand- induced dimerization, leading to autophosphorylation on specific tyrosine residues.
- PDGFR phosphorylation recruits signaling proteins containing Tyr(P)-binding domains.
- signaling proteins include Src kinase family members, phospholipase C-y1, the p38a subunit of PI3K, GTPase-activating protein.
- MAP Ras-mitogen activated protein
- PI3kinase-Akt the PI3kinase-Akt pathway
- PLC-y1 the PLC-y1
- Src the Src pathway.
- Activation of PDGFR ⁇ or PDGFR ⁇ by PDGFs leads to protein synthesis, proliferation, migration, protection against apoptosis and cellular transformation, key mechanisms associated with several vascular diseases including pulmonary hypertension.
- Platelet-derived growth factor (PDGF) and its receptors (PDGFR), including PDGFR ⁇ and PDGFR ⁇ play important roles in tumorigenesis, tumor progression, and the regulation of stromal cell function.
- PDGFR signaling is implicated in the development and progression of pulmonary hypertension.
- PDGFs are expressed in ECs, SMCs and macrophages and are strong mitogens and chemokines.
- Increased signaling through PDGFR ⁇ leads to smooth muscle cell proliferation which contributes to the development of vascular remodeling.
- PDGF and PDGF receptors ( ⁇ and ⁇ ) are upregulated in human and animals with pulmonary hypertension. Preclinically, efficacy in preventing and reversing vascular remodeling in experimentally induced pulmonary hypertension was demonstrated through non-selective inhibition of PDGF receptors.
- imatinib also known as Gleevec
- a non-selective tyrosine kinase inhibitor including PDGF receptors improved exercise capacity and hemodynamics in patients with advanced pulmonary hypertension.
- dasatinib a receptor tyrosine kinases inhibitor
- the disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein X is N or CH; R 1 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halogen, -CN, or C 1 -C 4 fluoroalkyl; R 7 is H, C 1 -C 6 alkyl, or -OC 1 -C 6 alkyl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted spiroheterocycloalkyl; R 3 and R 4 are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted spirocycloalkyl, or optionally substituted heterocycloalkyl; or one of R 3 or R 4 may be H
- compositions comprising such compounds, and methods of using such compounds in treating conditions in which PDGFR signaling is implicated are also provided.
- DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS [0011] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.
- compound refers to any specific chemical compound disclosed herein and includes tautomers, optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives, including prodrug and/or deuterated forms thereof where applicable.
- Deuterated small molecules contemplated are those in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by deuterium. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder.
- “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
- such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulf
- Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
- a “pharmaceutically acceptable excipient” refers to a substance that is non- toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
- a “solvate” refers to a physical association of a compound of formula (I) with one or more solvent molecules.
- alkyl when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C 1 - C 12 ”), preferably 1 to 6 carbons atoms (“C 1 -C 6 ”), in the group.
- alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, n-heptyl, n-octyl, and the like.
- the alkyl group is a C 1 -C 6 alkyl; in some embodiments, it is a C 1 -C 4 alkyl.
- a range of carbon atoms is used herein, for example, C 1 -C 6 , all ranges, as well as individual numbers of carbon atoms are encompassed.
- C 1 -C 3 includes C 1 -C 3 , C 1 -C 2 , C 2 -C 3 , C 1 , C 2 , and C 3 .
- cycloalkyl when used alone or as part of a substituent group refers to cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms (“C 3- C 10 ”), preferably from 3 to 6 carbon atoms (“C 3- C 6 ”).
- cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, indenyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[4.1.0]heptanyl, spiro[3.3]heptanyl, and spiro[3.4]octanyl.
- fluoroalkyl when used alone or as part of a substituent group refers to an alkyl group wherein one or more of the hydrogen atoms has been replaced with one or more fluorine atoms.
- fluoroalkyl groups examples include -CF 3 , CHF 2 , -CH 2 F and the like.
- the term “heterocycloalkyl” when used alone or as part of a substituent group refers to any three to twelve-membered monocyclic, saturated or partially unsaturated ring containing at least one heteroatom that is O, N or S.
- the heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.
- heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, and the like.
- bridged heterocycloalkyl ring refers to any 5 to 12 membered heterocycloalkyl ring system that contains at least one bridged ring.
- bridged heterocycloalkyl rings include azabicyclo[3.1.1]heptane, azabicyclo[3.1.1]heptane, azabicyclo[2.2.2]octane, azabicyclo[2.2.1]heptane, azabicyclo[2.1.1]hexane, azabicyclo[1.1.1]pentane, azabicyclo[1.1.1]pentane, 6-oxa-azabicyclo[3.1.1]heptane, 6- diazabicyclo[3.1.1]heptane, 3-thia-azabicyclo[3.1.1]heptane, and the like.
- fused heterocycloalkyl ring system refers to a heterocycloalkyl ring to which another ring is fused.
- the other ring that is fused to the heterocycle ring may be another heterocycloalkyl ring, a cycloalkyl ring, an aryl ring, or a heteroaryl ring.
- the fused heterocycloalkyl ring system is a 4 to 12 membered fused heterocycloalkyl ring system.
- spiroheterocycloalkyl ring system refers to a heterocycloalkyl ring that is substituted with a spirocyclic ring.
- the spirocyclic ring can be a cycloalkyl ring of a heterocycloalkyl ring.
- the spiroheterocycloalkyl ring system is a 5-12-membered spiroheterocycloalkyl ring system.
- halo or “halogen”, by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom.
- aryl when used alone or as part of a substituent group also refers to a mono- or bicyclic- aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted.
- aryl also includes a mono- or bicyclic- aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein two adjacent carbon atoms in the ring are optionally substituted such that said two adjacent carbon atoms and their respective substituents form a cycloalkyl or heterocycloalkyl ring.
- aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1, 2, 3,4-tetrahydronaphthyl, and the like.
- heteroaryl when used alone or as part of a substituent group refers to a mono- or bicyclic- aromatic ring structure including carbon atoms as well as up to four heteroatoms that are each independently nitrogen, oxygen, or sulfur. Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms. The heteroaryl moiety can be unsubstituted, or one or more of the carbon atoms in the ring can be substituted.
- heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl, benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3- b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-1H-indazole.
- a substituent may be optionally substituted with one or more of: halo (i.e., -F, -Cl, -Br, -I), cyano, -OH, -C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1- C 6 haloalkyl, -C 1 - C 6 alkoxy, -C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylamino, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C -6 al
- a substituent may be optionally substituted with one or more of: halo (i.e., -F, -Cl, -Br, -I), cyano, -C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, -C 1 -C 6 alkoxy, -C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylamino, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C- 6 alkyl) 2 , -NH(C 1 -C 6 alkoxy), -C(O)NHC 1 -C6 alkyl, -C(O)N(C 1 -C 6 alkyl) 2
- each of the above optional substituents are themselves optionally substituted by one or two groups.
- a substituent may be optionally substituted with one or more of: halo (i.e., -F, -Cl, -Br, -I), cyano, -OH, -C 1 -C 6 alkyl, -CH 2 CH 2 OH, - CH 2 CH 2 CH(OH)CH 2 (OH), -CH 2 CH(OH)CH 2 (OH), -CH 2 CH(OH)CH 3 , -CH 2 OH, -C (CH 3 ) 2 CH 2 (OH), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , -CH 2 -(C 3 -C 6 cycloalkyl), -C 3 -C 6 cycloalkyl, C 2 - C 6 alkenyl, C 2 -C 6 alkynyl, -C 1- C 6 haloal
- each of the above optional substituents are themselves optionally substituted by one or two groups.
- alkenyl refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C 2- C 12 ”), preferably 2 to 4 carbons atoms (“C 2 - C 4 ”), in the group, wherein the group includes at least one carbon-carbon double bond.
- alkynyl refers to a straight- or branched-chain group having from 1 to 12 carbon atoms (“C 1- C 12 ”), preferably 1 to 4 carbons atoms (“C 2 - C 4 ”), in the group, and wherein the group includes at least one carbon-carbon triple bond.
- alkynyl groups include ethynyl (-C ⁇ CH; C 2 alkynyl); propargyl (-CH 2 -C ⁇ CH; C 3 alkynyl), propynyl (-C ⁇ CCH 3 ; C 3 alkynyl); butynyl (-C ⁇ CCH 2 CH 3 ; C 4 alkynyl), pentynyl (-C ⁇ CCH 2 CH 2 CH 3 ; C 5 alkynyl), and the like.
- alkoxy refers to an oxygen radical attached to an alkyl group by a single bond.
- alkoxy groups examples include methoxy (-OCH 3 ), ethoxy (-OCH 2 CH 3 ), isopropoxy (-OCH(CH 3 ) 2 ) and the like.
- haloalkoxy refers to an oxygen radical attached to a haloalkyl group by a single bond. Examples of haloalkoxy groups include -OCF 3 , - OCH 2 CF 3 , -OCH(CF 3 ) 2 , and the like.
- haloalkyl refers to an alkyl group wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms.
- haloalkoxy refers to an alkoxy group wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms.
- stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space, e.g., enantiomers, diastereomers or tautomers.
- patient or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided.
- patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc.
- patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
- effective is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.
- Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (e.g., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.
- the disclosure is directed to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein X is N or CH; R 1 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halogen, -CN, or C 1 -C 4 fluoroalkyl; R 7 is H, C 1 -C 6 alkyl, or -OC 1 -C 6 alkyl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted spiroheterocycloalkyl; R 3 and R 4 are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted spirocycloalkyl, or optionally substituted heterocycloalkyl; or one of R 3 or R 4 may
- X in the compounds of formula (I) is N or CH. [0046] In some embodiments, X is N. [0047] In other embodiments, X is CH. [0048] In some aspects, R 1 in the compounds of formula (I) is H, C 1 -C 6 alkyl, C 3 - C 6 cycloalkyl, halogen, -CN, or C 1 -C 4 fluoroalkyl. [0049] In some embodiments, R 1 is H.
- R 1 is C 1 -C 6 alkyl, such as, for example, C 1 -C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like.
- R 1 is methyl.
- R 1 is C 3 -C 6 cycloalkyl, such as, for example, C 3 - C 5 cycloalkyl, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl, C 6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- R 1 is halogen, such as, for example, -F, -Cl, -Br, or -I.
- R 1 is -F.
- R 1 is -Cl.
- R 1 is cyano, i.e., -CN.
- R 1 is C 1 -C 4 fluoroalkyl, such as, for example, C 4 fluoroalkyl, C 3 fluoroalkyl, C 2 fluoroalkyl, C 1 fluoroalkyl, -CF 3 , -CHF 2 , or -CH 2 F.
- R 7 in the compounds of formula (I) is H, C 1 -C 6 alkyl, or - OC 1 -C 6 alkyl.
- R 7 is H.
- R 7 is C 1 -C 6 alkyl, such as, for example, C 1 -C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like.
- R 7 is methyl.
- R 7 is -OC 1 -C 6 alkyl, such as, for example, -OC 1 - C 6 alkyl, -OC 1 -C 5 alkyl, -OC 1 -C 4 alkyl, -OC 1 -C 3 alkyl, -OC 1 -C 2 alkyl, -OC 6 alkyl, -OC 5 alkyl, - OC 4 alkyl, -OC 3 alkyl, -OC 2 alkyl, -OC 1 alkyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n- butoxy, t-butoxy, iso-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and the like.
- R 7 is methoxy.
- R 2 in the compounds of formula (I) is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted spiroheterocycloalkyl.
- R 2 in the compounds of formula (I) is optionally substituted aryl, such as, for example, phenyl, indenyl, naphthyl, 1, 2, 3,4-tetrahydronaphthyl, and the like.
- R 2 is optionally substituted aryl
- the optionally substituted aryl is an optionally substituted phenyl.
- the optionally substituted phenyl is substituted with one or more -C(O)NH 2 , halogen, or -CN.
- the optionally substituted phenyl is substituted with one or more of -C(O)NH 2 , F, or -CN.
- the optionally substituted phenyl is substituted with one or more of -C(O)NH 2 , -C(O)NH(CH 2 CH 2 OCH 3 ), F, or -CN.
- the optionally substituted phenyl is 2-fluoro- benzamid-4-yl. [0071] In some embodiments, the optionally substituted phenyl is 2-fluoro- benzamid-5yl. [0072] In some embodiments, the optionally substituted phenyl is 2-fluoro-N- methyl-benzamid-4-yl. [0073] In some embodiments, the optionally substituted phenyl is 2-fluoro- benzonitril-4-yl. [0074] In some embodiments, the optionally substituted phenyl is 2-fluoro-N-(2- methoxyethyl)-benzamid-4-yl, i.e., : .
- R 2 in the compounds of formula (I) is optionally substituted heteroaryl, such as, for example, an optionally substituted pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl, benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)- one, tri
- R 2 in the compounds of formula (I) is optionally substituted pyrazolyl, optionally substituted pyridinyl, optionally substituted isothiazolyl, optionally substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl, or optionally substituted 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl.
- R 2 in the compounds of formula (I) is pyridin-2(1H)- one-6-yl.
- R 2 is optionally substituted heteroaryl
- the optionally substituted heteroaryl is substituted with optionally substituted C 1 -C 6 alkyl, optionally substituted 3-6 membered cycloalkyl, OC 1 -C 6 alkyl; optionally substituted 4-6 membered heterocycloalkyl, preferably oxetanyl, tetrahydropyranyl, or morpholinyl.
- R 2 is optionally substituted heteroaryl
- the optionally substituted heteroaryl is substituted with optionally substituted C 1 -C 6 alkyl, such as, for example, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 5 alkyl, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 -C 2 alkyl, optionally substituted C 6 alkyl, optionally substituted C 5 alkyl, optionally substituted C 4 alkyl, optionally substituted C 3 alkyl, optionally substituted C 2 alkyl, optionally substituted C 1 alkyl, optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted iso-propyl, optionally substituted n-butyl, optionally substituted t-butyl, optionally substituted iso-butyl,
- the optionally substituted C 1 -C 6 alkyl is -CH 3 , - CH(CH 3 )C(O)NH 2 , -CH 2 CH 2 C(O)NH 2 , -CH 2 CH 2 CN, or -CH 2 CH 2 OCH 3 .
- R 2 is optionally substituted heteroaryl
- the optionally substituted heteroaryl is substituted with optionally substituted 3-6 membered cycloalkyl, such as, for example, 3- membered cycloalkyl, 4-membered cycloalkyl, 5- membered cycloalkyl, or 6-membered cycloalkyl.
- the optionally substituted heteroaryl is substituted with -cyclopropyl.
- the optionally substituted heteroaryl is substituted with optionally substituted OC 1 -C 6 alkyl, such as, for example, optionally substituted OC 1 -C 6 alkyl, optionally substituted OC 1 -C 5 alkyl, optionally substituted OC 1 -C 4 alkyl, optionally substituted OC 1 -C 3 alkyl, optionally substituted OC 1 -C 2 alkyl, optionally substituted OC 6 alkyl, optionally substituted OC 5 alkyl, optionally substituted OC 4 alkyl, optionally substituted OC 3 alkyl, optionally substituted OC 2 alkyl, optionally substituted OC 1 alkyl, optionally substituted methoxy, optionally substituted ethoxy, optionally substituted n-propoxy, optionally substituted
- the optionally substituted heteroaryl is substituted with OCH 3 .
- the optionally substituted heteroaryl is substituted with optionally substituted 4-6 membered heterocycloalkyl, such as, for example, optionally substituted 4- membered heterocycloalkyl, optionally substituted 5- membered heterocycloalkyl, or optionally substituted 6- membered heterocycloalkyl.
- the optionally substituted 4-6 membered heterocycloalkyl is oxetanyl, tetrahydropyranyl, or morpholinyl.
- the optionally substituted heteroaryl is benzo[d]oxazol-2(3H)-one-5-yl.
- R 2 is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl.
- R 2 is 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3- yl.
- R 2 is 4,5,6,7-tetrahydro-3-pyrazolo[1,5-a]pyridine.
- R 2 is 7-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-3-yl.
- R 2 is 5-benzyl-7-methyl-4,5-dihydro-pyrazolo[1,5- a]pyrazin-6(7H)-one-3-yl.
- R 2 is 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridin-5-ol- 3-yl.
- R 2 is 2-methyl-6,7-dihydro-5H-pyrazolo[5,1- b][1,3]oxazin-6-ol-3-yl. [0095] In other embodiments, R 2 is 7-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-3-yl. [0096] In other embodiments, R 2 is 7-methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazin- 4(5H)-one-3-yl. [0097] In some embodiments wherein R 2 is optionally substituted heteroaryl, the optionally substituted heteroaryl is an optionally substituted 5-membered heteroaryl.
- R 2 is an optionally substituted pyrazolyl, an optionally substituted triazolyl, an optionally substituted isoxazolyl, an optionally substituted oxadiazolyl, an optionally substituted thiophenyl, or an optionally substituted thiazolyl.
- R 2 is optionally substituted heteroaryl
- the optionally substituted heteroaryl is an optionally substituted 6-membered heteroaryl.
- R 2 is an optionally substituted pyridinyl, or an optionally substituted pyrimidinyl.
- the optionally substituted heteroaryl is substituted with C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxyl, C 1 -C 6 alkoxyl, -C 1 -C 6 alk-O-C 1 -C 6 alkyl, hydroxyl, hydroxyalkyl, halo, cyano, cyclopropyl, 6-membered heterocycloalkyl, 5- membered heterocycloalkyl, 4-membered heterocycloalkyl, -C 1 -C 6 alk-SO 2 -C 1 -C 6 alkyl, 6- membered heteroaryl, 5-membered heteroaryl, -C(O)NH 2 , hydroxy-substituted-4-membered heterocycloalkyl, -C 1 -C 6 alk-CO 2 H, or -NH 2 .
- the optionally substituted heteroaryl is substituted with C 1 -C 6
- the optionally substituted heteroaryl is substituted with an optionally substituted C 1 -C 6 alkyl, such as, for example, C 1 -C 6 alkyl, C 1 - C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like; or an optionally substituted C 3 -C 5 cycloalkyl, such as, for example, C 3 cycloalky
- the optionally substituted heteroaryl is an optionally substituted 5-membered heteroaryl.
- the optionally substituted 5-membered heteroaryl is substituted with an optionally substituted C 1 -C 6 alkyl, such as, for example, C 1 - C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n- pentyl, n-hexyl, and the like; or an optionally substituted C 3 -C 5 cycl
- the optionally substituted 5-membered heteroaryl is an is an optionally substituted pyrrolyl.
- the optionally substituted pyrrolyl is an unsubstituted pyrrolyl.
- unsubstituted pyrrolyl is pyrrol-3-yl.
- the optionally substituted pyrrolyl is 1- (methylsulfonyl)-1H-pyrrol-3-yl.
- the optionally substituted 5-membered heteroaryl is an is an optionally substituted pyrazolyl.
- the optionally substituted pyrazolyl is an unsubstituted pyrazolyl.
- the unsubstituted pyrazolyl is pyrazol-1-yl.
- the unsubstituted pyrazolyl is pyrazol-3-yl.
- the unsubstituted pyrazolyl is pyrazol-4-yl.
- the optionally substituted pyrazolyl is substituted with an optionally substituted C 1 -C 6 alkyl, such as, for example, C 1 -C 6 alkyl, C 1 - C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like; or an optionally substituted C 3 -C 5 cycloalkyl, such as, for example, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl
- the optionally substituted pyrazolyl is substituted with a methyl group, i.e., -CH 3 .
- the optionally substituted pyrazolyl is substituted with a 2-hydroxyethyl group, i.e., -CH 2 CH 2 OH.
- the optionally substituted pyrazolyl is substituted with a 2-(C 1 -C 6 alkoxy)ethyl group, i.e., -CH 2 CH 2 O(C 1 -C 6 alkyl).
- the optionally substituted pyrazolyl is substituted with a 2-methoxyethyl group, i.e., -CH 2 CH 2 OCH 3 .
- the optionally substituted pyrazolyl is substituted with a cyclopropyl group.
- the optionally substituted pyrazolyl is 1- methyl-pyrazol-3-yl, 1-methyl-pyrazol-4-yl, 1-methyl-pyrazol-5-yl, 1-cyclopropyl-pyrazol-3- yl, 1-cyclopropyl-pyrazol-4-yl, 1-cyclopropyl-pyrazol-5-yl, 1-(2-hydroxyethyl)-pyrazol-3-yl, 1-(2-hydroxyethyl)-pyrazol-4-yl, 1-(2-hydroxyethyl)-pyrazol-5-yl, or 1-(2-methoxyethyl)- 1H-pyrazol-4-yl, and in particular optionally substituted pyrazolyl is 1-methyl-pyrazol-3-yl, 1-methyl-pyrazol-4-yl, 1-methyl-pyrazol-5-yl, 1-cyclopropyl-pyrazol-3-yl, 1-cyclopropyl- pyrazol-4
- the optionally substituted pyrazolyl is 3- methylpyrazol-4-yl. [00123] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1- ethylpyrazol-5-yl. [00124] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1- (cyclopropylmethyl)pyrazol-4-yl. [00125] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1- cyclobutanyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1-(2- methoxyethyl)-pyrazol-4-yl. [00127] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1-(2- methoxyethyl)-3,5-dimethyl-pyrazol-4-yl. [00128] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1- methyl-pyrazol-4-yl. [00129] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1- cyclopropyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1- methyl-pyrazol-5-yl.
- the optionally substituted pyrazolyl is substituted with two or three methyl groups.
- the optionally substituted pyrazolyl is 1,5- dimethyl-pyrazol-4-yl, 1,3-dimethyl-pyrazol-4-yl, 1-(2-methoxyethyl)-3,5-dimethyl-pyrazol- 4-yl, 3,5-dimethyl-pyrazol-4-yl, 1,4-dimethyl-pyrazol-5-yl, or 1,3,5-trimethyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1,3- dimethyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1,3- dimethyl-pyrazol-5-yl. [00135] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1,5- dimethyl-pyrazol-4-yl. [00136] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1- methyl-3-methoxy-pyrazol-4-yl. [00137] In some embodiments of R 2 , the optionally substituted pyrazolyl is 1,3,5- trimethyl-pyrazol-4-yl. [00138] In some embodiments of R 2 , the optionally substituted pyrazolyl is 3,5- dimethyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1- methyl-3-trifluoromethyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1- trifluoromethyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1-(2,2,2- trifluoroeth-1-yl)-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1- difluoromethylpyrazol-4-yl.
- the optionally substituted pyrazolyl is 3,5- dimethyl-1-(2-methoxyethyl)-pyrazol-4-yl. [00144] In other embodiments of R 2 , the optionally substituted pyrazolyl is 3,5- dimethyl-1-(oxetan-3-yl)-1H-pyrazol-4-yl. [00145] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1- (thietan-3-yl 1,1-dioxide)-pyrazol-4-yl, i.e., .
- the optionally substituted pyrazolyl is 1- (oxetan-3-yl)-1H-pyrazol-4-yl. [00147] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1- (oxetan-3-yl-methyl)-pyrazol-4yl. [00148] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1- ((methylsulfonyl)methyl)-pyrazol-4-yl. [00149] In other embodiments of R 2 , the optionally substituted pyrazolyl is 5- (methoxymethyl)-1-methyl-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1- (tetrahydrofuran-3-yl)-pyrazol-4-yl. [00151] In other embodiments of R 2 , the optionally substituted pyrazolyl is (R)-1- (tetrahydrofuran-3-yl)-pyrazol-4-yl. [00152] In other embodiments of R 2 , the optionally substituted pyrazolyl is (S)-1- (tetrahydrofuran-3-yl)-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1- (tetrahydro-2H-pyran-4-yl)-pyrazol-4-yl. [00154] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1- ((cyano)methyl)-pyrazol-4-yl. [00155] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(1- (cyano)eth-1-yl)-pyrazol-4-yl. [00156] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(2- (cyano)eth-1-yl)-pyrazol-4-yl.
- the optionally substituted pyrazolyl is (1- hydroxy-2-methylpropan-2-yl)-1H-pyrazol-4-yl
- the optionally substituted pyrazolyl is 1- (acetamid-2-yl)-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1-(N- methylacetamid-2-yl)pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1- (propanamid-3-yl)-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1-(N- methylacetamid-2-yl)-pyrazol-4-yl. [00162] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1- (propanamide-2-yl)-pyrazol-4-yl. [00163] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(4- piperidinyl)-pyrazol-4-yl. [00164] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1-(2,3- dihydroxy-propan-1-yl)-pyrazol-3-yl. [00166] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(2,3- dihydroxy-propan-1-yl)-pyrazol-4-yl. [00167] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(2- hydroxy-propan-1-yl)-pyrazol-4-yl. [00168] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(3,4- dihydroxy-butan-1yl)-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1-((3- hydroxy-isoxazol-5-yl)methyl)-pyrazol-4-yl. [00170] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-((3- benzyloxy-isoxazol-5-yl)methyl)-pyrazol-4-yl. [00171] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1- (pyridin-3-yl)-pyrazol-4-yl.
- the optionally substituted pyrazolyl is 3- (hydroxymethyl)-1-methyl-pyrazol-4-yl. [00173] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(1- hydroxy-2-methylpropan-2-yl)-pyrazol-4-yl. [00174] In other embodiments of R 2 , the optionally substituted pyrazolyl is 1-(3- N,N-dimethylaminopropan-1-yl)pyrazol-4-yl.
- the optionally substituted pyrazolyl is 1-(4- tetrahydro-2H-thiopyran 1,1-dioxide)-pyrazol-4-yl, i.e., .
- the optionally substituted 5-membered heteroaryl is an is an optionally substituted triazolyl.
- the optionally substituted triazolyl is substituted with an optionally substituted C 1 -C 6 alkyl, such as, for example, C 1 -C 6 alkyl, C 1 - C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like; or an optionally substituted C 3 -C 5 cycloalkyl, such as, for example, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl
- the optionally substituted 5-membered heteroaryl is 2,4-dimethyl-1,2,3-triazol-5-yl. [00179] In some embodiments of R 2 , the optionally substituted 5-membered heteroaryl is 2-methyl-1,2,3-triazol-4-yl. [00180] In some embodiments of R 2 , the optionally substituted 5-membered heteroaryl is an optionally substituted imidazolyl. [00181] In some embodiments of R 2 , the optionally substituted imidazolyl is 1- methyl-imidazol-4-yl.
- the optionally substituted imidazolyl is 1- methyl-imidazol-5-yl.
- the optionally substituted 5-membered heteroaryl is an optionally substituted isoxazolyl.
- the optionally substituted isoxazolyl is 3,5- dimethyl-isoxazol-4-yl.
- the optionally substituted 5-membered heteroaryl is an optionally substituted isothiazolyl.
- the optionally substituted 5-membered heteroaryl is isothiazol-4-yl.
- the optionally substituted 5-membered heteroaryl is an optionally substituted furanyl.
- the optionally substituted furanyl is 2- (hydroxymethyl)-furan-5-yl.
- the optionally substituted 5-membered heteroaryl is furan-3-yl.
- the optionally substituted 5-membered heteroaryl is an optionally substituted thiophenyl.
- the optionally substituted thiophenyl is thiopheny-3-yl.
- the optionally substituted thiophenyl is 2- hydroxymethyl-thiophen-5-yl.
- R 2 in the compounds of formula (I) is an optionally substituted 6-membered heteroaryl.
- the optionally substituted 6-membered heteroaryl is an optionally substituted pyridinyl, an optionally substituted pyridazinyl, or an optionally substituted pyrimidinyl.
- the optionally substituted 6-membered heteroaryl is substituted with an optionally substituted C 1 -C 6 alkyl, such as, for example, C 1 - C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n- pentyl, n-hexyl, and the like; or an optionally substituted C 3 -C 5 cycloalkyl, such as, for example, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloal
- the optionally substituted 6-membered heteroaryl is an is an optionally substituted pyridinyl.
- the optionally substituted pyridinyl is substituted with an optionally substituted C 1 -C 6 alkyl, such as, for example, C 1 -C 6 alkyl, C 1 - C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like; or an optionally substituted C 3
- the optionally substituted pyridinyl is unsubstituted pyridinyl.
- the unsubstituted pyridinyl is pyridine-2-yl.
- the unsubstituted pyridinyl is pyridine-3-yl.
- the unsubstituted pyridinyl is pyridine-4-yl.
- the optionally substituted pyridinyl is C 1 - C 6 alkoxyl substituted pyridinyl.
- the optionally substituted pyridinyl is methoxy substituted pyridinyl, such as, for example, 4-methoxypyridin-3-yl. [00204] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- methoxypyridin-3-yl. [00205] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- methoxypyridin-5-yl. [00206] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- methoxypyridin-6-yl.
- the optionally substituted pyridinyl is 4- methoxypyridin-3-yl. [00208] In some embodiments of R 2 , the optionally substituted pyridinyl is 3- methoxypyridin-4-yl. [00209] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- ethoxypyridin-3-yl. [00210] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- trifluoromethoxypyridin-3-yl. [00211] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- hydroxypyridin-3-yl.
- the optionally substituted pyridinyl is 2- hydroxypyridin-5-yl. [00213] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- methylpyridin-3-yl. [00214] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- methylpyridin-4-yl. [00215] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- methylpyridin-5-yl. [00216] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- ethylpyridin-3-yl.
- the optionally substituted pyridinyl is 2-(2- fluoroethoxy)pyridin-3-yl. [00218] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- amino-3-fluoro-pyridin-5-yl. [00219] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- amino-pyridin-5-yl or 6-aminopyridin-3-yl. [00220] In some embodiments of R 2 , the optionally substituted pyridinyl is 2-(4- morpholinyl)-pyridin-4-yl.
- the optionally substituted pyridinyl is 2- (dimethylamino)pyridin-4-yl. [00222] In some embodiments of R 2 , the optionally substituted pyridinyl is 3- (methylsulfonyl)pyridin-5-yl. [00223] In some embodiments of R 2 , the optionally substituted pyridinyl is: In some embodiments of R 2 , the optionally substituted pyridinyl is: [00225] [00226] In some embodiments of R 2 , the optionally substituted pyridinyl is 4- (acetylamino)-pyridin-2-yl.
- the optionally substituted pyridinyl is 3- (acetylamino)-pyridin-5-yl. [00228] In some embodiments of R 2 , the optionally substituted pyridinyl is 2- (acetylamino)-pyridin-4-yl. [00229] In some embodiments of R 2 , the optionally substituted pyridinyl is 2-(N- methylacetamid)-pyridin-4-yl, i.e., . [00230] In some embodiments of R 2 , the optionally substituted 6-membered heteroaryl is an is an optionally substituted pyridazinyl.
- the optionally substituted pyridaziny is 3- methyl-pyridazin-5-yl. [00232] In some embodiments of R 2 , the optionally substituted pyridaziny is 3,6- dimethoxy-pyridazin-4-yl. [00233] In some embodiments of R 2 , the optionally substituted pyridaziny is 3- hydroxy-pyridazin-6-yl. [00234] In some embodiments of R 2 , the optionally substituted 6-membered heteroaryl is an is an optionally substituted pyrimidinyl.
- the optionally substituted pyrimidinyl is pyrimidin-5-yl.
- the optionally substituted pyrimidinyl is 2- methoxy-4-hydroxy-pyrimidin-5-yl.
- the optionally substituted pyrimidinyl is 2,4- dimethoxy-pyrimidin-5-yl.
- the optionally substituted pyrimidinyl is 4- methyl-pyrimidin-5-yl.
- the optionally substituted heteroaryl is an optionally substituted 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine.
- the optionally substituted 6,7-dihydro-5H- pyrazolo[5,1-b][1,3]oxazine is 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl.
- the optionally substituted heteroaryl is 6,7- dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-3-yl.
- the optionally substituted heteroaryl is 5,6- dihydro-8H-imidazo[2,3-c][1,4]oxazin-3-yl.
- the optionally substituted heteroaryl is 7,8- dihydro-5H-imidazo[3,2-c][1,3]oxazin-3-yl.
- the optionally substituted heteroaryl is an optionally substituted 1-methylindazol-4-yl.
- the optionally substituted heteroaryl is an optionally substituted 1H-pyrazolo[3,4-b]pyridin-1-yl.
- the optionally substituted 1H-pyrazolo[3,4- b]pyridin-1-yl is unsubstituted 1H-pyrazolo[3,4-b]pyridin-1-yl.
- the optionally substituted heteroaryl is an optionally substituted 1H-pyrazolo[3,4-b]pyridine-5-yl
- the optionally substituted heteroaryl is an optionally substituted indolyl.
- the optionally substituted indolyl is an unsubstituted indolyl.
- the unsubstituted indolyl is indol-3-yl.
- the optionally substituted heteroaryl is 2-oxo- 2,3-dihydrobenzo[d]oxazol-5-yl.
- R 2 in the compounds of formula (I) is optionally substituted heterocycloalkyl.
- the optionally substituted heterocycloalkyl is an optionally substituted dihydropyran, an optionally substituted tetrahydropyran, or an optionally substituted morpholine.
- the optionally substituted heterocycloalkyl is substituted with hydroxy, hydroxyalkyl, C 1 -C 6 alkoxyl, or -C 1 -C 6 alk-O-C 1 -C 6 alkyl.
- the optionally substituted heterocycloalkyl is
- the optionally substituted heterocycloalkyl is 1-(2-fluoroethyl)-2-oxo-1,2-dihydropyridin-3-yl.
- the optionally substituted heterocycloalkyl is 1-methyl-6-oxo-1,6-dihydropyridin-3-yl.
- the optionally substituted heterocycloalkyl is morpholin-4-yl.
- n in the compounds of formula (I) is 1, 2, or 3.
- n in the compounds of formula (I) is 1.
- n in the compounds of formula (I) is 2. [00262] In some embodiments, n in the compounds of formula (I) is 3. [00263] In some aspects of the compounds of formula (I), L is -C(O)NH-, - NHC(O)O-, -NHC(O)-, -NHC(O)NH-, or -NHC(O)NR 8 -, wherein when L is -NHC(O)NR 8 -, an R 5 or an R 6 attached to a carbon atom, together with R 8 , form a heterocycloalkyl ring; and wherein when L is -C(O)NH-, -NHC(O)O-, -NHC(O)NR 8 -, or -NHC(O)NH-, n is 2 or 3, and when L is -NHC(O)-, n is 1, 2, or 3.
- n is 1 and L is - NHC(O)-.
- n is 2, or 3 L is - NHC(O)-.
- n is 2 and L is - NHC(O)-.
- n is 3 and L is - NHC(O)-.
- n is 2, or 3 and L is -C(O)NH-.
- n is 2 and L is - C(O)NH-.
- n is 3 and L is - C(O)NH-.
- n is 2, or 3 and L is -NHC(O)O-.
- n is 2 and L is - NHC(O)O-.
- n is 3 and L is - NHC(O)O-.
- n is 2 or 3 and L is -NHC(O)NH.
- n is 2 and L is - NHC(O)NH.
- n is 3 and L is - NHC(O)NH.
- n is 2 or 3 and L is -NHC(O)NR 8 - wherein an R 5 or an R 6 attached to a carbon atom, together with R 8 , form a heterocycloalkyl ring.
- n is 2 or 3 and L is -NHC(O)NR 8 - wherein an R 5 or an R 6 attached to a carbon atom, together with R 8 , form a heterocycloalkyl ring, the structure o u a s .
- the structure formula (I) is .
- the heterocycloalkyl ring is a 4-membered heterocycloalkyl ring.
- n is 2 and L is - NHC(O)NR 8 - wherein an R 5 or an R 6 attached to a carbon atom, together with R 8 , form a heterocycloalkyl ring.
- n is 3 and L is - NHC(O)NR 8 - wherein an R 5 or an R 6 attached to a carbon atom, together with R 8 , form a heterocycloalkyl ring.
- R 3 and R 4 in the compounds of formula (I) are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted spirocycloalkyl, or optionally substituted heterocycloalkyl; or one of R 3 or R 4 in the compounds of formula (I) may be H.
- one of R 3 or R 4 in compounds of formula (I) is H.
- R 3 or R 4 in the compounds of formula (I) is optionally substituted aryl, such as, for example, optionally substituted phenyl, indenyl, naphthyl, or 1,2,3,4-tetrahydronaphthyl.
- R 3 or R 4 in the compounds of formula (I) is optionally substituted heteroaryl, such as, for example, optionally substituted pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8- tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3- b]pyridinyl, quinazolinyl-4(3H)
- R 3 or R 4 in the compounds of formula (I) is pyridinyl. In some embodiments, R 3 or R 4 in the compounds of formula (I) is 2-pyridinyl. [00289] In some embodiments, R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is optionally substituted alkyl, such as, for example, optionally substituted C 1 -C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso- butyl, sec-butyl, n-pentyl, n-he
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 3 .
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 2 CH(CH 3 ) 2 .
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 2 CH 2 CH 3 .
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH(CH 3 ) 2 .
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -C(CH 3 ) 3 .
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 2 CH 2 OCH 3 .
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 2 CH 2 OH.
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 2 -cyclohexyl.
- R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 2 -cyclopentyl. [00299] In some embodiments, R 3 or R 4 in the compounds of formula (I) or the compounds of formula (I) is -CH 2 -cyclopropyl.
- R 3 or R 4 in the compounds of formula (I) is optionally substituted cycloalkyl, such as, for example, optionally substituted C 3 - C 7 cycloalkyl, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl, C 6 cycloalkyl, C 7 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
- R 3 or R 4 in the compounds of formula (I) is optionally substituted cyclopentyl.
- R 3 or R 4 in the compounds of formula (I) is unsubstituted cyclopentyl. [00303] In some embodiments, R 3 or R 4 in the compounds of formula (I) is optionally substituted cyclobutyl. [00304] In some embodiments, R 3 or R 4 in the compounds of formula (I) is 1- methyl-cyclobut-1-yl. [00305] In some embodiments, R 3 or R 4 in the compounds of formula (I) is unsubstituted cyclobutyl. [00306] In some embodiments, R 3 or R 4 in the compounds of formula (I) is optionally substituted cyclohexyl.
- R 3 or R 4 in the compounds of formula (I) is unsubstituted cyclohexyl.
- R 3 or R 4 in the compounds of formula (I) is optionally substituted cycloheptyl.
- R 3 or R 4 in the compounds of formula (I) is unsubstituted cycloheptyl.
- R 3 or R 4 in the compounds of formula (I) is optionally substituted heterocycloalkyl, such as, for example, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, isoxazolidinyl, oxazolidinyl, pyrazolidinyl, imidazolidinyl, or thiazolidinyl.
- R 3 or R 4 in the compounds of formula (I) is tetrahydropyran-4-yl.
- R 3 is optionally substituted alkyl or optionally substituted C 4 -C 5 cycloalkyl; and R 4 is optionally substituted C 4 -C 5 cycloalkyl or optionally substituted heteroaryl.
- heterocycloalkyl rings include the following: [00315]
- the optionally substituted 3-12-membered heterocycloalkyl ring is an optionally substituted azetidinyl, an optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted azepanyl, optionally substituted piperazinyl, optionally substituted oxazepanyl, optionally substituted thiomorpholinyl 1,1-dioxide, or optionally substituted morpholinyl.
- the optionally substituted 3-12-membered heterocycloalkyl ring is . [00317] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is . [00318] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is . [00319] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is . [00320] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is . [00321] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is .
- the optionally substituted 3-12-membered heterocycloalkyl ring is . [00323] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is . [00324] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is . [00325] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is . [00326] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is .
- the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with at least one C 1 -C 6 alkyl group, such as, for example, C 1 -C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec- butyl, n-pentyl, n-hexyl, and the like.
- C 1 -C 6 alkyl group such as, for example, C 1 -C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 al
- the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with at least one -CH 3 group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2,2-dimethylpyrrolidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,3-dimethylpyrrolidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,3-dimethylazetidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2,2-dimethylazetidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-isopropylazetidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-methyl-pyrrolidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (R)-2-methyl-pyrrolidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-2-methyl-pyrrolidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-methyl-piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (R)-2-methyl-piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-2-methyl-piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-methyl-piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (R)-3-methyl-piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-3-methyl-piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-methyl-piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (R)-4-methyl-piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-4-methyl-piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-hydroxymethyl-piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-methoxy-piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (R)-4- methoxy -piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-4- methoxy -piperidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1,2,5-trimethyl-4-piperazinyl: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (2S, 5R)-1,2,5-trimethyl-4-piperazinyl.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (2S, 5S)-1,2,5-trimethyl-4-piperazinyl.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (2R, 5R)-1,2,5-trimethyl-4-piperazinyl.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (2R, 5S)-1,2,5-trimethyl-4-piperazinyl.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form .
- the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with a cyclopropyl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-methoxymethyl-pyrrolidin-1-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (R)-2- methoxymethyl-pyrrolidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-2- methoxymethyl-pyrrolidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-methoxy-pyrrolidin-1-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (R)-3-methoxy-pyrrolidin-1-yl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-3-methoxy-pyrrolidin-1-yl group.
- the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with at least one halogen atom.
- the halogen atom is -F.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4,4-difluoropiperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-fluoropiperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-hydroxypiperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4,4-dimethylpiperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-(methoxymethyl)piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-(cyanomethyl)piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-(acetamid-2-yl)piperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2,2-dimethylpiperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2,2-dimethylpiperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,3-difluoropiperidin-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-morpholinyl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-methylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(R)-methylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(S)-methylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-ethylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(R)-ethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(S)-ethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,5-dimethylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(R),5(R)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(S),5(S)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(R),5(S)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(S),5(R)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,5-dimethylpiperidinyl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(R),5(R)- dimethylpiperidinyl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(S),5(S)- dimethylpiperidinyl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(R),5(S)- dimethylpiperidinyl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(S),5(R)- dimethylpiperidinyl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,3-dimethylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2,2-dimethylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2,6-dimethylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2(R),6(R)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2(S),6(S)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2(R),6(S)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2(S),6(R)-dimethylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-methylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(R)-methylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3(S)-methylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-methylmorpholino group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2(R)-methylmorpholino group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2(S)-methylmorpholino group.
- the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with a 5-membered heteroaryl group.
- the 3-12-membered heterocycloalkyl ring substituted with a 5-membered heteroaryl group is a pyrrolidinyl ring substituted with a 5- membered heteroaryl group or a piperidinyl ring substituted with a 5-membered heteroaryl group.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- bridged heterocycloalkyl ring systems include:
- the optionally substituted 5- to 12-membered bridged heterocycloalkyl ring is an optionally substituted 7-azabicyclo[2.2.2]octan-7-yl, an optionally substituted 7-azabicyclo[2.2.1]heptan-7-yl, an optionally substituted 2- azabicyclo[2.2.1]heptan-2-yl, an optionally substituted azabicyclo[3.1.1]heptane, an optionally substituted 8-azabicyclo[3.2.1]octan-8-yl, an optionally substituted 2,5- diazabicyclo[2.2.1]heptan-5-yl, an optionally substituted 6-azabicyclo[3.2.1]octan-6-yl, an optionally substituted 3-azabicyclo[3.2.1]octan-3-yl, an optionally substituted 2- azabicyclo[2.2.2]octan-2yl, an optionally substituted diazabicyclo[2.2.1]
- the optionally substituted 5-12-membered bridged heterocycloalkyl ring is substituted with C 1 -C 6 alkyl, hydroxy, or hydroxyalkyl.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-azabicyclo[2.2.2]octan-2-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form an 9-azabicyclo[3.3.1]nonan-9-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form an 3-azabicyclo[3.1.1]heptan-3-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form an 3-azabicyclo[3.2.1]octan-3-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form an 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form an 6-oxa-3-azabicyclo[3.1.1]heptan-3-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form (1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (1R,4S)-2-azabicyclo[2.2.1]heptan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form (1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 8-oxa-3-azabicyclo[3.2.1]octan-3-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azabicyclo[2.2.2]octan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7-azabicyclo[2.2.1]heptan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-azabicyclo[2.2.1]heptan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- Non-limiting examples of such ring systems include:
- the optionally substituted 5-12-membered spiroheterocycloalkyl ring is an optionally substituted 7-azaspiro[3.5]nonan-7-yl, an optionally substituted 4-azaspiro[2.4]heptan-4-yl, an optionally substituted 1- azaspiro[3.3]heptan-1-yl, an optionally substituted 2-azaspiro[3.3]heptan-2-yl, an optionally substituted 6-azaspiro[2.5]octan-6-yl, an optionally substituted 2-oxa-7-azaspiro[4.4]nonan- 7-yl, an optionally substituted 1-oxa-7-azaspiro[4.4]nonan-7-yl, an optionally substituted 2- oxa-6-azaspiro[3.4]octan-6-yl, an optionally substituted 5-azaspiro[2.4]heptan-5-yl, an optionally substituted 4-azaspir
- the optionally substituted 5-12-membered spiroheterocycloalkyl ring is substituted with C 1 -C 6 alkyl, halo, or hydroxyalkyl.
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-azaspiro[2.4]heptan-4-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5-azaspiro[3.4]octan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6-azaspiro[3.4]octan-6-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6-azaspiro[2.5]octan-6-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7-azaspiro[3.5]nonan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-azaspiro[2.5]octan-4-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5-azaspiro[2.5]octan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-azaspiro[3.3]heptan-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-azaspiro[3.3]heptan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6-fluoro-2-azaspiro[3.3]heptan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7-oxa-2-azaspiro[3.5]nonan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-6-azaspiro[3.3]heptan-6-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5-oxa-2-azaspiro[3.5]nonan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5-azaspiro[2.4]heptan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azaspiro[3.5]nonan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-6-azaspiro[3.5]nonan-6-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7-azaspiro[4.4]nonan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-azaspiro[4.4]nonan-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-7-azaspiro[4.4]nonan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-oxa-7-azaspiro[4.4]nonan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azaspiro[3.4]octan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-6-azaspiro[3.4]octan-6-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 8-oxa-1-azaspiro[4.5]decan-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 8-oxa-2-azaspiro[4.5]decan-2-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 8-methyl-1,8-diazaspiro[4.5]decan-1-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-7-azaspiro[3.5]nonan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7-oxa-4-azaspiro[2.5]octan-4-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-oxa-7-azaspiro[2.5]octan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 8-oxa-5-azaspiro[3.5]nonan-5-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5-oxa-8-azaspiro[3.5]nonan-8-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2,5-dioxa-8-azaspiro[3.5]nonan-8-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-oxa-7-azaspiro[3.5]nonan-7-yl group, .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-azaspiro[4.5]decan-2-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-azaspiro[4.5]decan-1-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5-azaspiro[3.5]nonan-5-yl group, N .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6-azaspiro[4.5]decan-6-yl group, N .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-oxa-9-azaspiro[5.5]undecan-9-yl group, .
- R 3 and R 4 in the compounds of formula (I), together with the nitrogen atom to which they are both attached form an optionally substituted 4-12- membered fused heterocycloalkyl ring system.
- Non-limiting examples of such ring systems include:
- the optionally substituted 4-12-membered fused heterocycloalkyl ring system is an optionally substituted 3-azabicyclo[3.2.0]heptan-3-yl, an optionally substituted 3-azabicyclo[3.1.0]hexan-3-yl, an optionally substituted 2- azabicyclo[3.1.0]hexan-2-yl, an optionally substituted hexahydro-1H-2-pyrrolo[2,1- c]pyrazinyl, an optionally substituted 5,8-dihydro-6H-7-1,7-naphthyridinyl, an optionally substituted hexahydro-2H-6-furo[2,3-c]pyridinyl, an optionally substituted tetrahydro-1H,3H- 5-furo[3,4-c]pyrrolyl, an optionally substituted 2-oxa-5-azabicyclo[4.1.0]heptanyl, an optionally substituted 4,
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,4-dihydro-2,7-naphthyridin-2(1H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-methyl-4,5-dihydro-1H-pyrazolo[3,4-c]pyridin-6(7H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5H-pyrrolo[3,4-b]pyridin-6(7H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5,7-dihydro-pyrrolo[3,4-b]pyrazin-6-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-isoindoline group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-methyl-3,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-methyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1-methyl-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5,6-dihydro-8H-[1,2,4]triazolo[5,1-c]pyrazin-7-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-5H-[1,2,4]triazolo[1,5-c]pyrimidin-6-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4,7-dihydro-5H-6-thieno[2,3-c]pyridine-6-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5,6-dihydro-1,7-naphthyridin-7(8H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl group: S N N .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-methyl-6,7-dihydro-4H-oxazolo[4,5-c]pyridin-5-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-methyl-6,7-dihydro-4H-oxazolo[5,4-c]pyridine-5-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,4-dihydro-2,6-naphthyridin-2(1H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-1,6-naphthyridin-6(5H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5,6-dihydro-8H-imidazo[5,1-c]pyrazin-7-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6,7-dihydro-4H-pyrazolo[5,1-c]pyrazin-5-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6,7-dihydro-4H-[1,2,3]triazolo[5,1-c]pyrazin-5-yl group: they are both attached, form a 4H-pyrrolo[3,4-d]thiazol-5(6H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 1H-pyrrolo[3,4-c]pyridin-2(3H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a hexahydro-2H-6-furo[2,3-c]pyridine-6-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a tetrahydro-1H-2-pyrrolo[2,1-c]pyrazin-4(3H)-one group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (S)-tetrahydro-1H-2-pyrrolo[2,1-c]pyrazin-4(3H)-one group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3-azabicyclo[3.2.0]heptan-3-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a (1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-azabicyclo[3.1.0]hexan-2-yl group: N .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 4-azatricyclo[3.3.0.0 1,3 ]octanyl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3,4-dihydroisoquinolin-2(1H)-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 3',4'-dihydro-spirocyclopropane-1,1'-isoquinolin-2-yl group: .
- R 3 and R 4 together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azabicyclo[4.1.0]heptan-5-yl group: .
- each R 5 and each R 6 in the compounds of formula (I) independently H, C 1 -C 6 alkyl, or C 3 -C 5 cycloalkyl; or an R 5 and R 6 attached to the same carbon atom, together with that carbon atom, may form a C 3 -C 6 cycloalkyl ring, or an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system.
- R 5 or R 6 in the compounds of formula (I) is H.
- R 5 or R 6 in the compounds of formula (I) is C 1 - C 6 alkyl, such as, for example, C 1 -C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, C 1 -C 2 alkyl, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, methyl, ethyl, n-propyl, iso-propyl, n- butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, and the like.
- R 5 or R 6 is methyl (i.e., -CH 3 ).
- an R 5 and an R 6 are methyl (i.e., -CH 3 ).
- R 5 or R 6 in the compounds of formula (I) is C 3 - C 5 cycloalkyl, such as, for example, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like.
- an R 5 and R 6 in the compounds of formula (I) attached to the same carbon atom, together with that carbon atom form a cyclopropyl group.
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system.
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, such as, for example, an optionally substituted azetidnyl ring, an optionally substituted pyrrolidinyl ring, or an optionally substituted piperidinyl ring.
- the optionally substituted 3-12-membered heterocycloalkyl ring is a 4-8 membered heterocycloalkyl ring.
- the structure formula (I) is .
- the structure formula (I) is .
- the structure formula (I) is [00549] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is [00550] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is [00551] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is .
- the structure formula (I) is .
- the structure formula (I) is .
- the structure formula (I) is .
- the structure formula (I) is .
- the structure formula (I) is [00558] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is [00559] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is [00560] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is
- the structure formula (I) is [00574] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is [00575] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is , , .
- the structure formula (I) is [00577] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is [00578] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is , , .
- the structure formula (I) is [00579] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is [00580] In some embodiments of the compounds of formula (I) wherein an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure formula (I) is .
- the structure formula (I) is .
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 3-12-membered heterocycloalkyl ring
- the structure formula (I) is .
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 3-12-membered .
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 3-12-membered .
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 3-12-membered .
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 3-12-membered .
- an R 5 or R 6 together with an R 3 or R 4 may form an optionally substituted 4-12-membered fused heterocycloalkyl ring system.
- the structure formula (I) is .
- the structure formula (I) is .
- an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 5-12-membered bridged heterocycloalkyl ring.
- an R 5 or R 6 , together with an R 3 or R 4 may form an optionally substituted 5-12-membered spiroheterocycloalkyl ring system.
- the compounds according to formula (I) are those that have an IC 50 ⁇ 20 nM in a PDGFR cellular assay such as, for example, that described in the Examples section below.
- the compounds according to formula (I) are those that have an IC 50 ⁇ 5 nM in a PDGFR cellular assay such as, for example, that described in the Examples section below.
- the compound of the disclosure is one of Examples 1-90, or a pharmaceutically acceptable salt thereof, as described in the Examples section below.
- the compound of the disclosure is one of Examples 91- 190, or a pharmaceutically acceptable salt thereof, as described in the Examples section below.
- Stereoisomers of compounds of formula (I) are also contemplated by the present disclosure.
- the disclosure encompasses all stereoisomers and constitutional isomers of any compound disclosed or claimed herein, including all enantiomers and diastereomers.
- Pharmaceutically acceptable salts and solvates of the compounds of formula (I) are also within the scope of the disclosure.
- Isotopic variants of the compounds of formula (I) are also contemplated by the present disclosure.
- Pharmaceutical compositions and methods of administration [00601] The subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.
- the pharmaceutical compositions contain a compound of the present disclosure or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- the subject pharmaceutical compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions.
- the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.
- the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above
- the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%
- the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.
- the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.
- the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009
- the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g
- the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.
- the compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day.
- the amount of the compounds described herein are set forth on a free base basis. That is, the amounts indicate that amount of the compound administered, exclusive of, for example, solvent (such as in solvates) or counterions (such as in pharmaceutically acceptable salts).
- solvent such as in solvates
- counterions such as in pharmaceutically acceptable salts.
- the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration.
- the composition further contains: (iv) an effective amount of a third agent.
- the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption.
- compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in- water emulsion, or a water-in-oil liquid emulsion.
- dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients.
- compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
- a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent.
- Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds.
- water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf- life or the stability of formulations over time.
- Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
- compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
- An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.
- An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier can take a wide variety of forms depending on the form of preparation desired for administration.
- any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose.
- suitable carriers include powders, capsules, and tablets, with the solid oral preparations.
- Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.
- natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrol
- suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle.
- Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form.
- a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein.
- the amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition.
- Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.
- Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof.
- Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof.
- a lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.
- the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.
- the tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.
- a suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10.
- HLB hydrophilic-lipophilic balance
- Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.
- Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable.
- lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10.
- Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di
- ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.
- Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG- phosphatidylethanolamine, PVP -phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, cap
- Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene stea,
- the polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.
- Other hydrophilic-non-ionic surfactants include, without limitation, PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG- 12 oleate, PEG- 15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG- 15 stearate, PEG-32 distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG- 10
- Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof.
- preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.
- the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection.
- a solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.
- suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as t
- solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N- methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide.
- solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.
- the amount of solubilizer that can be included is not particularly limited.
- the amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art.
- the solubilizer can be in a weight ratio of 10%, 25%o, 50%), 100%o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%>, 2%>, 1%) or even less. Typically, the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight. [00637]
- the composition can further include one or more pharmaceutically acceptable additives and excipients.
- additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
- an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons.
- Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like.
- bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para- bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like.
- a pharmaceutically acceptable acid such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids
- Salts of polyprotic acids such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used.
- the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like.
- Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.
- Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like.
- suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like.
- compositions for injection [00640]
- the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection. Components and amounts of agents in the compositions are as described herein.
- the forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
- Aqueous solutions in saline are also conventionally used for injection.
- Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- certain desirable methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Pharmaceutical compositions for topical (e.g. transdermal) delivery are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- certain desirable methods of preparation are vacuum-drying and freeze
- the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.
- Compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions.
- DMSO dimethylsulfoxide
- carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients.
- compositions may provide more immediate exposure of the active ingredient to the chosen area.
- the pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are many of these penetration- enhancing molecules known to those trained in the art of topical formulation.
- humectants e.g., urea
- glycols e.g., propylene glycol
- alcohols e.g., ethanol
- fatty acids e.g., oleic acid
- surfactants e.g., isopropyl myristate and sodium lauryl sulfate
- pyrrolidones e.g., isopropyl myristate and sodium lauryl sulfate
- pyrrolidones e.glycerol monolaurate, sulfoxides, terpenes (e.g., menthol)
- amines amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.
- transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos.5,023,252, 4,992,445 and 5,001,139.
- patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
- compositions for inhalation may be delivered as a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
- a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
- the inhalation device may be an aerosol vial provided with a valve adapted to deliver a metered dose, i.e. a metered dose inhaler.
- the inhalation device may be a nebulizer, such as an airjet nebulizer, or an ultrasonic nebulizer, or a hand- held nebulizer, sometimes referred to as a soft mist or soft spray inhaler, or a mechanical device which allows much smaller nebulized volumes than conventional nebulizers.
- a nebulizer such as an airjet nebulizer, or an ultrasonic nebulizer, or a hand- held nebulizer, sometimes referred to as a soft mist or soft spray inhaler
- a mechanical device which allows much smaller nebulized volumes than conventional nebulizers.
- Such devices are referred to in, for example, WO2013030802.
- the inhalation device may be, for example, a dry powder inhalation device adapted to deliver dry powder from a capsule or blister containing a dry powder comprising a dosage unit or a multidose dry powder inhalation (MDPI) device adapted to deliver dry powder comprising a dosage unit upon actuation.
- the dry powder composition preferably contains a diluent or carrier, such as lactose, and a compound that helps to protect against product performance deterioration due to moisture e.g. magnesium stearate.
- the invention also includes (A) a compound of the invention, or a pharmaceutically acceptable salt thereof, in inhalable form; (B) an inhalable medicament comprising the compound in inhalable form together with a pharmaceutically acceptable carrier in inhalable form; (C) a pharmaceutical product comprising such a compound in inhalable form in association with an inhalation device; and (D) an inhalation device containing such a compound in inhalable form.
- A a compound of the invention, or a pharmaceutically acceptable salt thereof, in inhalable form
- B an inhalable medicament comprising the compound in inhalable form together with a pharmaceutically acceptable carrier in inhalable form
- C a pharmaceutical product comprising such a compound in inhalable form in association with an inhalation device
- D an inhalation device containing such a compound in inhalable form.
- compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art.
- Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally. [00657] The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician.
- an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day. [00658] In some embodiments, a compound of the invention is administered in a single dose.
- a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day.
- a compound of the invention in another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary. [00661] Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
- compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty.
- compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis.
- a compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent.
- a compound of the invention is admixed with a matrix.
- a matrix may be a polymeric matrix, and may serve to bond the compound to the stent.
- Polymeric matrices suitable for such use include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters.
- lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copo
- Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds.
- Compounds of the invention may be applied to the surface of the stent by various methods such as dip/spin coating, spray coating, dip-coating, and/or brush-coating.
- the compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent.
- the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall.
- Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash.
- compounds of the invention may be covalently linked to a stent or graft.
- a covalent linker may be used which degrades in vivo, leading to the release of the compound of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages.
- Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty.
- Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.
- a variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U.S. Pat. No.5451233; U.S. Pat. No.5040548; U.S. Pat. No.5061273; U.S. Pat. No. 5496346; U.S. Pat. No.5292331; U.S. Pat. No.5674278; U.S. Pat. No.3657744; U.S. Pat. No.4739762; U.S. Pat. No.5195984; U.S.
- the compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.
- a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half- life than the compound of the invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly.
- the subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
- the pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
- Methods of Use [00669] The method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention.
- the therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein.
- the specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
- references herein to methods of treatment using one or more compounds or formulations thereof, or methods of using the compounds described herein to treat a disease or disorder should also be interpreted as references to: (i) one or more compounds or formulations thereof for use in methods of treatment; and/or (ii) the use of one or more compounds or formulations thereof in the manufacture of a medicament for treating a pathological condition set forth herein.
- the disclosure also relates to methods of using the compounds described herein to treat in a subject in need thereof, a disease or disorder in which PDGFR signaling is implicated. These methods are accomplished by administering to the subject a compound of the disclosure in an amount effective to treat the disease or disorder.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is pulmonary hypertension (PH).
- the pulmonary hypertension is pulmonary arterial hypertension (PAH) (WHO PH Group 1); PH secondary to heart failure (WHO PH Group 2); PH secondary to lung diseases and/or hypoxia (WHO PH Group 3); PH due to pulmonary artery obstruction (WHO Group 4); or PH due to unknown or rare diseases (WHO PH Group 5).
- PAH pulmonary arterial hypertension
- WHO PH Group 1 PH secondary to heart failure
- WHO PH Group 3 PH secondary to lung diseases and/or hypoxia
- WHO PH Group 4 PH due to pulmonary artery obstruction
- PH due to unknown or rare diseases WHO PH Group 5
- the PAH (WHO PH Group 1) is idiopathic PAH, PAH with vasoreactivity, heritable PAH, drugs and toxins-induced PAH, PAH associated with connective tissue disease, PAH associated with HIV infection, PAH associated with portal hypertension, PAH associated with congenital heart disease, PAH associated with schistosomiasis, PAH in long-term responders to calcium channel blockers, PAH with overt signs of venous/capillaries involvement; persistent PH of the Newborn syndrome; or systemic sclerosis-associated PAH (SSc-PAH).
- SSc-PAH systemic sclerosis-associated PAH
- the PAH secondary to heart failure (WHO PH Group 2) is PH due to heart failure with preserved ejection fraction, PH due to heart failure with reduced ejection fraction, valvular heart disease, or congenital post-capillary obstructive lesions.
- the PH secondary to lung diseases and/or hypoxia (WHO PH Group 3) is PH due to obstructive lung disease, PH due to restrictive lung disease, PH due to other lung diseases with mixed restrictive/obstructive pattern, PH due to hypoxia without lung disease, PH due to developmental lung disorders.
- the PH due to obstructive lung disease is PH due to chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the PH due to restrictive lung disease is PH due to interstitial lung diseases (ILDs).
- the PH due to interstitial lung diseases (ILDs) is PH due to idiopathic pulmonary fibrosis (IPF).
- the PH due to pulmonary artery obstruction is chronic thromboembolic PH (CTEPH) or PH due to other pulmonaty artery obstructions.
- the PH due to unknown or rare diseases is PH due to hematologic disorders, PH due to systemic disorders, PH due to other disorders, or PH due to complex congenital heart disease.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a respiratory disease.
- the respiratory disease is asthma.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a fibrotic disease.
- the fibrotic disease is pulmonary fibrosis, cardiac fibrosis or liver fibrosis.
- the fibrotic disease is pulmonary fibrosis.
- the pulmonary fibrosis is an interstitial lung disease.
- the interstitial lung disease is idiopathic pulmonary fibrosis.
- the interstitial lung disease is rheumatoid arthritis- associated interstitial lung disease.
- the interstitial lung disease is systemic sclerosis- associated interstitial lung disease.
- the interstitial lung disease is connective tissue disease-associated interstitial lung disease.
- the interstitial lung disease is nonspecific interstitial pneumonia.
- the interstitial lung disease is unclassifiable interstitial lung disease.
- the interstitial lung disease is hypersensitivity pneumonitis.
- the interstitial lung disease is sarcoidosis.
- the interstitial lung disease is non-idiopathic pulmonary fibrosis interstitial lung disease.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a dermatological disease.
- the dermatological disease or disorder is atopic dermatitis, scleroderma, or urticaria.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is an inflammatory disease or disorder.
- the inflammatory disease or disorder is allergic rhinitis, irritable bowel syndrome (IBS); or inflammatory bowel disease (IBD).
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is an autoimmune disorder.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a metabolic disease.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is vascular restenosis; age-related macular degeneration (AMD); irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); obesity-cell related diseases; type I diabetes or type II diabetes.
- AMD age-related macular degeneration
- IBS irritable bowel syndrome
- IBD inflammatory bowel disease
- obesity-cell related diseases type I diabetes or type II diabetes.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is pulmonary arterial hypertension (PAH).
- PAH pulmonary arterial hypertension
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to heart failure (WHO PH Group 2).
- WHO PH Group 2 PH secondary to heart failure
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to heart failure with preserved ejection fraction.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to heart failure with reduced ejection fraction.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is valvular heart disease.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is congenital post-capillary obstructive lesions.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to lung diseases and/or hypoxia (WHO PH Group 3).
- WHO PH Group 3 the disease or disorder is PH secondary to lung diseases and/or hypoxia
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to pulmonary artery obstruction (WHO Group 4).
- WHO Group 4 pulmonary artery obstruction
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is chronic thromboembolic PH (CTEPH).
- CTEPH chronic thromboembolic PH
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to unknown or rare diseases (WHO PH Group 5).
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is idiopathic PAH.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PAH associated with connective tissue disease.
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is systemic sclerosis-associated PAH (SSc-PAH).
- SSc-PAH systemic sclerosis-associated PAH
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to interstitial lung diseases (ILDs).
- ILDs interstitial lung diseases
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to idiopathic pulmonary fibrosis (IPF).
- an effective amount of a pharmaceutical agent according to the disclosure is administered to a subject suffering from or diagnosed as having such a disease or disorder.
- An "effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic benefit in patients in need of such treatment for the designated disease or disorder.
- Effective amounts or doses of the compounds of the present disclosure may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease or disorder, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
- An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID).
- an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
- the compounds of the disclosure may be used in combination with additional active ingredients in the treatment of the above diseases or disorders.
- the additional active ingredients may be coadministered separately with a compound of the disclosure or included with such an agent in a pharmaceutical composition according to the disclosure.
- the combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the disclosure), decrease one or more side effects, or decrease the required dose of the active agent according to the disclosure.
- Ethyl 2-(5- chloropyrazin-2-yl)acetate (1-1) is reacted with N,N-dimethylformamide dimethyl acetal, optionally in a solvent such as ethanol, to give ethyl 2-(5-chloropyrazin-2-yl)-3- (dimethylamino)acrylate (1-2).
- Ethyl 2-(5-chloropyrazin-2-yl)-3-(dimethylamino)acrylate (1- 2) is treated with ammonium acetate in the presence of acetic acid, optionally in a solvent such as 1,4-dioxane, to give ethyl 3-amino-2-(5-chloropyrazin-2-yl)acrylate (1-3), which is treated with (diacetoxyiodo)benzene in a solvent such as dichloromethane to give intermediate 1.
- Scheme 2 [00726] Scheme 2 illustrates the synthesis of intermediates 2, wherein R 7 is OCH 3 or CH 3 .
- the intermediates 1 or 2 is coupled with boronic ester or boronic acid (3-1), in the presence of a catalyst such as PdCl 2 (dppf), Pd(Ph 3 ) 4 , a base such as Cs 2 CO 3 , K 2 CO 3 , Na 2 CO 3 , K 3 PO 4 , and in a solvent such as dioxane-water, DME-water; to give compound (3-2).
- a catalyst such as PdCl 2 (dppf), Pd(Ph 3 ) 4
- a base such as Cs 2 CO 3 , K 2 CO 3 , Na 2 CO 3 , K 3 PO 4
- a solvent such as dioxane-water, DME-water
- the ester of compound (3-2) is hydrolyzed in the presence of a base such as LiOH, NaOH, in a solvent such as THF-water, THF-MeOH-water, to give intermediate acid 3.
- Scheme [00728] Scheme 4 illustrates an alternate synthesis
- 2-Chloropyrazine is coupled with boronic ester or boronic acid (3-1), in the presence of a catalyst such as PdCl 2 (dppf), Pd(Ph 3 ) 4 , a base such as Cs 2 CO 3 , K 2 CO 3 , Na 2 CO 3 , K 3 PO 4 , and in a solvent such as dioxane-water, DME-water; to give pyrazine compound (4-1).
- the pyrazine (4-1) is reacted with O-(mesitylsulfonyl)hydroxylamine in a solvent such as dichloromethane to give compound (4-2).
- the aldehyde (I-4) is reacted with amine (I-5), in the presence of a reducing reagent such as Na(OAc) 3 BH, NaCNBH 3 , in a solvent such as 1,2-dichloroethan, MeOH, optionally in the presence of an acid such as acetic acid, to give an amine compound (I-6).
- a reducing reagent such as Na(OAc) 3 BH, NaCNBH 3
- a solvent such as 1,2-dichloroethan, MeOH
- an acid such as acetic acid
- the nitro group of compound I-6 is reduced by hydrogen, in the presence of a catalyst such as Pd/C, in a solvent such as THF, to give aminopyridine compound I-7.
- Compound I-7 is coupled with intermediate 3, in the presence of a coupling agent such as TCFH, in the presence of NMI, in a solvent such as CH 2 Cl 2 , CH 3 CN, to yield Formula I.
- Pyridinyl acid (I-8) is coupled with diamine compound (I-9), in the presence of a coupling reagent such as TCFH, EDCI, HATU, optionally in the presence of NMI, in a solvent such as CH 3 CN, CH 2 Cl 2 , pyridine, to give amide compound (I-10).
- This amide compound (I-10) is coupled with intermediate 3, in the presence of a coupling reagent such as TCFH, in the presence of NMI, in a solvent such as CH 3 CN, CH 2 Cl 2 , to yield Formula I.
- Pyridinyl acid (I-8) is coupled with diamine compound (I-9), in the presence of a coupling reagent such as TCFH, EDCI, HATU, optionally in the presence of NMI, in a solvent such as CH 3 CN, CH 2
- the nitropyridinylamine (I-11) is reacted with an acid chloride (I-12), in the presence of a base such as TEA, in a solvent such as DCM, to give chloro compound (I-13) which is then treated with an amine (I-5), in the presence of a base such as K 2 CO 3 , in a solvent such as CH 3 CN, DMF, to give amine compound (I-14).
- the nitropyridinylamine (I-11) is reacted with acid (I-15), in the presence of a coupling reagent such as TCFH, in the presence of NMI, in a solvent such as CH3CN, CH2Cl2, to give compound (I-14).
- a coupling reagent such as TCFH
- NMI in a solvent such as CH3CN, CH2Cl2
- a catalyst such as Pd/C
- THF solvent such as THF
- the aminopyridine compound (I-16) is reacted with intermediate 3, in the presence of a coupling reagent such as TCFH, in the presence of NMI, in a solvent such as CH 3 CN, CH 2 Cl 2 , to yield Formula I.
- the aminopyridine compound is reacted with acid I-17, in the presence of a coupling reagent such as TCFH, in the presence of NMI, in a solvent such as CH 3 CN, CH 2 Cl 2 , to give the chloro compound (I-18), which is coupled with boronated reagent (3-1), in the presence of a catalyst such as PdCl 2 (dppf), in the presence of a base such as Cs 2 CO 3 , and in a solvent such as dioxane-water to give Formula I.
- the intermediate 3 is coupled with aminopyridine (I-19), in the presence of a coupling reagent such as HATU, EDCI, in the presence of a base such as DIEA, in a solvent such as DMF, pyridine, to give amide compound (I-20).
- a coupling reagent such as HATU, EDCI
- a base such as DIEA
- DMF dioxane
- pyridine a solvent such as DMF
- the Boc protecting group of compound (I-20) is deprotected with an acid such HCl, TFA, in a solvent such as 1,4- dioxane, CH 2 Cl 2 , to give the amine (I-21).
- the pyridinylamine (I-21) is reacted with acryloyl chloride, in the presence of a base such as Et 3 N, in a solvent such as CH 2 Cl 2 , to give acrylamide (I-22), which is reacted with amine (I-5), in the presence of a base such as K 2 CO 3 , Cs 2 CO 3 , in a solvent such as MeOH, to give Formula I.
- Scheme 10
- the nitropyridinylamine (I-11) is reacted with protected cyclic amine (I-23), in the presence of a coupling reagent such as HATU, TCFH, in the presence of NMI when the coupling reagent is TCFH, optionally in the presence of a base such as DIEA, in a solvent such as DMF, CH 2 Cl 2 , CH 3 CN, to give the amide compound (I-24).
- a coupling reagent such as HATU, TCFH
- NMI when the coupling reagent is TCFH
- a base such as DIEA
- a solvent such as DMF, CH 2 Cl 2 , CH 3 CN
- the amine protecting group (such as Boc group) of compound (I-24) is deprotected with an acid such as HCl, TFA, in a solvent such as EtOAc, 1,4-dioxane, CH 2 Cl 2 , to give cyclic amine (I-25).
- the cyclic amine (I-25) is reacted with an alkylating reagent (I-26), wherein X is a leaving group such as I, Br, Cl, OTs, in the presence of a base such as K 2 CO 3 , Cs 2 CO 3 , in a solvent such as CH 3 CN, DMF, to give amine compound (I-28).
- the cyclic amine (I-25) is subjected to a reductive amination with a carbonyl compound (I-27), in the presence of a reduction reagent such as NaCNBH3, Na(OAc)3BH, optionally in the presence of an acid such as HOAc, in a solvent such as MeOH, 1,2-dichloroethan, to give the amine compound (I-28).
- a reduction reagent such as NaCNBH3, Na(OAc)3BH
- an acid such as HOAc
- a solvent such as MeOH, 1,2-dichloroethan
- the pyridinylamine (I-21) is reacted with protected cyclic amine (I-23), in the presence of a coupling reagent such as EDCI, in a solvent such as pyridine, to give amide compound (I-30).
- the amine protecting group (such as Boc group) of compound (I-30) is deprotected with an acid such as HCl, TFA, in a solvent such as EtOAc, 1,4-dioxane, CH 2 Cl 2 , to give cyclic amine (I-31).
- the cyclic amine (I-31) is reacted with an alkylating reagent (I-26), wherein X is a leaving group such as I, Br, Cl, OTs, in the presence of a base such as K 2 CO 3 , Cs 2 CO 3 , in a solvent such as CH 3 CN, DMF, to give Formula I.
- an alkylating reagent I-26
- X is a leaving group such as I, Br, Cl, OTs
- a base such as K 2 CO 3 , Cs 2 CO 3
- a solvent such as CH 3 CN, DMF
- the cyclic amine (I-31) is subjected to a reductive amination with a carbonyl compound (I-27), in the presence of a reduction reagent such as NaCNBH 3 , Na(OAc) 3 BH, optionally in the presence of an acid such as HOAc, in a solvent such as MeOH, 1,2-dichloroethan, to give Formula
- Example 9 N-(5-(2-((1R,4S)-2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(1- methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide Step 1.
- Example 50 N-(5-(2-((1R,4S)-2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3-yl)-6- (1,3-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide Step 1.
- the reaction was stirred at 80 °C for 1 h.
- the mixture was purified by Prep-HPLC [Column: XBridge Prep OBD C18 Column, 19*250 mm, 5 ⁇ m; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 ), Mobile Phase B: MeOH; Flow rate: 25 mL/min; Gradient: 43% B to 57% B in 10 min; Wave Length: 254 nm] to afford the N-(5-(3-(2-azabicyclo[2.2.2]octan-2-yl)propanamido)-2-methylpyridin-3-yl)-6-(1-methyl- 1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide as a off-white solid (22.0 mg, 16.4% yield).
- Example 78 N-(5-((2S,4R)-1,4-dimethylpyrrolidine-2-carboxamido)-2-methylpyridin-3-yl)-6-(1- methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide Step 1.
- the purified product was then purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5 ⁇ m; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 ), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 16% B to 41% B in 9 min; Wave Length: 254/220 nm] to afford N-(5-((2S,4R)-1,4-dimethylpyrrolidine-2- carboxamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- 3-carboxamide as a off-white solid (25.7 mg, 27.6% yield).
- the reaction mixture was concentrated and the residue was first purified by C18 column with CH 3 CN/water with 0.05% TFA (5%-30%).
- the purified product was purified again by Prep-HPLC [Column: XBridge Shield RP18 OBD Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH 4 HCO 3 ), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 24% B to 46% B in 8 min; Wave Length: 254/220 nm] to give N-(5-(2-(1- (cyclopentylmethyl)pyrrolidin-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H- pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide as a white solid (45.0 mg, 20.1% yield).
- Example 85 N-(5-(1-cycloheptylazetidine-3-carboxamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H- pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide Step 1.
- the residue was first purified by C18 column chromatography with ACN/H 2 O (0.05% NH 4 HCO 3 ) (0 ⁇ 60%).
- the purified product was purified again by Prep-HPLC with the following conditions: [Column: Xselect CSH C18 OBD Column 30*150mm 5 ⁇ m; Mobile Phase A: H 2 O (0.05%HCl ), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 5% B to 18% B in 5 min; Wave Length: 254/220 nm] to afford N-(5-(1-cyclohexylazetidine-3-carboxamido)-2-methylpyridin-3-yl)-6-(pyridin-4- yl)pyrazolo[1,5-a]pyrazine-3-carboxamide (14.6 mg, 16.2% yield) as a yellow solid.
- Example 90 N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(4- carbamoyl-3-fluorophenyl)pyrazolo[1,5-a]pyrazine-3-carboxamide [00802] A mixture of N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2- methylpyridin-3-yl)-6-(4-cyano-3-fluorophenyl)pyrazolo[1,5-a]pyrazine-3-carboxamide (Example 46, 100 mg, 0.19 mmol) in H 2 SO 4 (2 mL) and TFA (2 mL) was stirred at 60°C for 1 h.
- reaction mixture was concentrated and the resulting residue was stirred in H 2 O ( ⁇ 30ml). The resulting mixture was filtered and the solid was washed again with H 2 O. The resulting solid was collected and washed with 20%MeOH/CH 2 Cl 2 and filtered (2x).
- Example 106 N-(5-(3-((2,2-dimethylpyrrolidin-1-yl)methyl)azetidine-1-carboxamido)-2- methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3- carboxamide Step 1.
- the reaction was diluted with 10%MeOH/CH 2 Cl 2 and filtered. The solution was concentrated and the residue was suspended in 1N HCl (5 mL) and washed with EtOAc (2x). The remaining aqueous layer was basified with aq. NaHCO 3 and filtered.
- reaction mixture was cooled to 0°C and NaBH 3 CN (45 mg, 0.716 mmol) was added. The resulting mixture was warmed up to room temperature and stirred for 1 hour. The reaction was quenched with H 2 O (10 mL).
- Example 137 (R*)-N-(5-(1-(3,3-dimethylbutan-2-yl)azetidine-3-carboxamido)-2- methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3- carboxamide
- Example 138 (S*)-N-(5-(1-(3,3-dimethylbutan-2-yl)azetidine-3-carboxamido)-2- methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3- carboxamide [00824] N-(5-(1-(3,3-dimethylbutan-2-yl)azetidine-3-carboxamido)-2- methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo
- Example 158 N-(5-(2-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2- methylpyridin-3-yl)-7-methyl-4-oxo-4,5,6,7-tetrahydro-[3,6'-bipyrazolo[1,5-a]pyrazine]- 3'-carboxamide
- Step a ethyl 1-(1-((tert-butoxycarbonyl)amino)propan-2-yl)-4-iodo-1H-pyrazole-5- carboxylate
- Di-tert-butyl azodicarboxylate (4.67 g, 20.3 mmol) was added to a stirred solution of ethyl 4-iodo-1H-pyrazole-5-carboxylate (3 g, 11.28 mmol), tert-butyl (2- hydroxypropyl)carbamate (4.44 g, 22.
- Step b ethyl 1-(1-aminopropan-2-yl)-4-iodo-1H-pyrazole-5-carboxylate
- a 4M solution of HCl in 1,4-dioxane (10 mL, 40 mmol) was added to a solution of ethyl 1-(1-((tert-butoxycarbonyl)amino)propan-2-yl)-4-iodo-1H-pyrazole-5- carboxylate (4.2 g, 9.63 mmol) in acetonitrile (20 mL). The mixture was stirred at 80 °C for 2 h.
- Step d 7-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7- dihydropyrazolo[1,5-a]pyrazin-4(5H)-one
- 2-MeTHF 2-MeTHF
- isopropylmagnesium chloride (1.88 mL, 2 M, 3.77 mmol) rapidly dropwise (clear solution which becomes turbid) and the ice bath was removed.
- Step e N-(5-(2-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3- yl)-7-methyl-4-oxo-4,5,6,7-tetrahydro-[3,6'-bipyrazolo[1,5-a]pyrazine]-3'-carboxamide
- Step b tert-butyl 7-methyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate [00842] To a solution of 7-methyl-4H,5H,6H,7H-pyrazolo[1,5-A]pyrazine (250 mg, 1.82 mmol) in DCM (25 mL) was added BOC-anhydride (437.5 mg, 2 mmol) and the reaction was stirred at rt under nitrogen overnight.
- Step c tert-butyl 7-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7- dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate
- 2-MeTHF 2-MeTHF
- reaction was cooled to room temperature, concentrated, dissolved in DCM, loaded onto a silica precolumn, dried, and purified by flash column, 0 - 50% EtOAc/heptane to yield tert-butyl 7-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (216 mg, 56%) as an impure white gum.
- the product was used without further purification in next reaction.
- Step d N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7- methyl-4,5,6,7-tetrahydro-[3,6'-bipyrazolo[1,5-a]pyrazine]-3'-carboxamide
- reaction was stirred with Si-trisamine for 2.5 h, filtered, and purified by prep-HPLC, 10% - 32% MeCN/water/0.1% TFA. to yield a pale yellow solid which was dissolved in DCM and treated with an equal volume of TFA to yield a bright yellow solution which was allowed to stand at rt for 20 min.
- reaction mixture was filtered through a Si-thiol cartridge to remove metals and purified by flash column, 12% - 32% MeCN/water/0.1% TFA to yield a tan solid which was dissolved in DCM and treated with an equal volume of TFA and the resulting orange solution was allowed to stand at rt.
- Step b 5-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine
- 2-MeTHF 3-methyl-1,10- phenanthroline
- Step c N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(5- hydroxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyrazolo[1,5-a]pyrazine-3- carboxamide
- the reaction was diluted with 50 mL EtOAc, washed 3x water then 1x brine, filtered through cotton, and concentrated to a clear colorless oil.
- the crude oil was purified by flash column, 0 - 10% EtOAc/heptane to yield 2-((1,3-dibromopropan-2- yl)oxy)tetrahydro-2H-pyran (1.23 g, 88%) as a clear colorless oil.
- Step b 2-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-6,7-dihydro-5H-pyrazolo[5,1- b][1,3]oxazine
- Step c 2-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine
- Step d N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(6- hydroxy-2-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)pyrazolo[1,5- a]pyrazine-3-carboxamide
- a mixture of 6-chloro-N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2- methylpyridin-3-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide 60 mg, 0.081 mmol
- Step b N-((1H-pyrazol-5-yl)methyl)-1-phenylmethanamine
- tert-butyl ((1H-pyrazol-5-yl)methyl)(benzyl)carbamate (6 g, 20.88 mmol) in EtOAc (20 mL) in a 500 mL round bottle of equipped with an addition funnel was chilled in an ice bath under nitrogen.
- HCl (1M in EtOAc, 50 mL, 50 mmol) was transferred via cannula to the addition funnel, then added rapidly dropwise. After the addition was complete, the ice bath was removed, and the reaction was stirred at rt. Slow gas evolution and formation of precipitate. Left stirring over the weekend.
- Step c 5-benzyl-7-methyl-4,5-dihydropyrazolo[1,5-a]pyrazin-6(7H)-one
- a suspension of N-((1H-pyrazol-5-yl)methyl)-1-phenylmethanamine (0.58 g, 2.59 mmol) under nitrogen in DCM (7.5 mL) in a 50 mL round bottle flask was treated with DIPEA (2.68 mL, 15.56 mmol) and the mixture was stirred until a clear solution resulted.
- the solution was chilled on an ice bath, 2-chloropropionyl chloride (0.38 mL, 3.89 mmol) was added dropwise, and the ice bath was removed.
- Step d 5-benzyl-7-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5- dihydropyrazolo[1,5-a]pyrazin-6(7H)-one
- 2-MeTHF 2-MeTHF
- Step e 5-benzyl-N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)- 7-methyl-6-oxo-4,5,6,7-tetrahydro-[3,6'-bipyrazolo[1,5-a]pyrazine]-3'-carboxamide
- a mixture of 6-chloro-N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2- methylpyridin-3-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide 65 mg, 0.087 mmol
- 5-benzyl- 7-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5-dihydropyrazolo[1,5-a]pyrazin- 6(7H)-one 83 mg, 0.23 mmol
- reaction mixture was filtered through a Si-thiol cartridge to remove metals and purified by flash column, 9% - 29% MeCN/water/0.1% TFA to yield 5-benzyl-N-(5-(2-(2,2-dimethylpyrrolidin-1- yl)acetamido)-2-methylpyridin-3-yl)-7-methyl-6-oxo-4,5,6,7-tetrahydro-[3,6'-bipyrazolo[1,5- a]pyrazine]-3'-carboxamide (17 mg, 30%) as a pale yellow solid.
- Step b N-(5-amino-2-fluorophenyl)-6-chloropyrazolo[1,5-a]pyrazine-3-carboxamide hydrochloride [00861] To a suspension of tert-butyl (3-(6-chloropyrazolo[1,5-a]pyrazine-3- carboxamido)-4-fluorophenyl)carbamate (759 mg, 1.15 mmol) in MeOH (10 mL) under nitrogen was added HCl (4M in dioxane, 6 mL, 24 mmol) to yield a clear yellow solution, which was heated to 50°C. After 30 min the reaction was cooled and concentrated to a yellow solid.
- Step c 6-chloro-N-(5-(2-chloroacetamido)-2-fluorophenyl)pyrazolo[1,5-a]pyrazine-3- carboxamide
- N-(5-amino-2-fluorophenyl)-6- chloropyrazolo[1,5-a]pyrazine-3-carboxamide hydrochloride 770 mg, 1.13 mmol
- DIPEA 0.87 mL, 5.06 mmol
- Step d N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-fluorophenyl)-6- chloropyrazolo[1,5-a]pyrazine-3-carboxamide
- 6-chloro-N-(5-(2-chloroacetamido)-2- fluorophenyl)pyrazolo[1,5-a]pyrazine-3-carboxamide 297 mg, 0.78 mmol
- 2- azabicyclo[2.2.1]heptane 96 mg, 0.99 mmol
- Cs 2 CO 3 760 mg, 2.33 mmol
- Step e N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-fluorophenyl)-6-(1-methyl- 1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- a mixture of N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2- fluorophenyl)-6-chloropyrazolo[1,5-a]pyrazine-3-carboxamide 43 mg, 0.097 mmol
- 1- methylpyrazole-4-boronic acid, pinacol ester 46 mg, 0.21 mmol
- cesium carbonate 98 mg, 0.3 mmol
- 1,1'-bis(diphenylphosphino)ferrocenedichloro palladium(II) (10.5 mg, 0.014 mmol) in 1,4-dioxane
- Example 169 N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-fluorophenyl)-7- methyl-4,5,6,7-tetrahydro-[3,6'-bipyrazolo[1,5-a]pyrazine]-3'-carboxamide
- reaction was gravity filtered through a Si-thiol column and purified by prep-HPLC, 23% - 43% MeCN/water/0.1% TFA to yield a yellow solid which was dissolved in ⁇ 1 mL DCM and an equal volume of TFA.
- Example 172 N-(5-(2-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2- methylpyridin-3-yl)-6-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- Step a ethyl 6-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrazine-3-carboxylate
- Step b 6-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrazine-3-carboxylic acid
- ethyl 6-(1H-pyrazol-1-yl)pyrazolo[1,5- a]pyrazine-3-carboxylate 38 mg, 0.15 mmol
- 1,4-dioxane 1.5 mL
- a clear colorless solution of LiOH 11 mg, 0.46 mmol
- the reaction was concentrated and acidified with 1N HCl.
- Step c N-(5-(2-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3- yl)-6-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- Step b N-(5-amino-2-fluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyrazine-3-carboxamide hydrochloride [00872] To a suspension of tert-butyl (4-fluoro-3-(6-(1-methyl-1H-pyrazol-4- yl)pyrazolo[1,5-a]pyrazine-3-carboxamido)phenyl)carbamate (124 mg, 0.27 mmol) in MeOH (2 mL) was added HCl (4M in dioxane, 1 mL, 4 mmol) to yield a clear yellow solution with exotherm.
- Step c N-(5-(2-chloroacetamido)-2-fluorophenyl)-6-(1-methyl-1H-pyrazol-4- yl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- N-(5-amino-2-fluorophenyl)-6-(1-methyl-1H- pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide hydrochloride 55 mg, 0.14 mmol
- DIPEA 61 ⁇ L, 0.35 mmol
- Example 175. N-(2-fluoro-5-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)- yl)acetamido)phenyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3- Step a: tert-butyl (3-(6-chloropyrazolo[1,5-a]pyrazine-3-carboxamido)-4- fluorophenyl)carbamate [00876] A mixture of 6-chloropyrazolo[1,5-a]pyrazine-3-carboxylic acid (212 mg, 1.07 mmol), tert-butyl 3-amino-4-fluorophenylcarbamate [361548
- Step b N-(5-amino-2-fluorophenyl)-6-chloropyrazolo[1,5-a]pyrazine-3-carboxamide hydrochloride
- tert-butyl (3-(6-chloropyrazolo[1,5-a]pyrazine-3- carboxamido)-4-fluorophenyl)carbamate 506 mg, 1.07 mmol
- MeOH MeOH
- HCl 4M in dioxane
- Step c 6-chloro-N-(5-(2-chloroacetamido)-2-fluorophenyl)pyrazolo[1,5-a]pyrazine-3- carboxamide
- N-(5-amino-2-fluorophenyl)-6- chloropyrazolo[1,5-a]pyrazine-3-carboxamide hydrochloride 507 mg, 1.19 mmol
- DIPEA 0.9 mL, 5.22 mmol
- 2-chloroacetyl chloride (0.14 mL, 1.78 mmol
- Step d 6-chloro-N-(2-fluoro-5-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)- yl)acetamido)phenyl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- a mixture of 6-chloro-N-(5-(2-chloroacetamido)-2- fluorophenyl)pyrazolo[1,5-a]pyrazine-3-carboxamide 68 mg, 0.18 mmol
- hexahydro-1H- furo[3,4-C]pyrrole 40 mg, 0.35 mmol
- Cs 2 CO 3 116 mg, 0.36 mmol
- Step e N-(2-fluoro-5-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)acetamido)phenyl)- 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- a mixture of 6-chloro-N-(2-fluoro-5-(2-(tetrahydro-1H-furo[3,4-c]pyrrol- 5(3H)-yl)acetamido)phenyl)pyrazolo[1,5-a]pyrazine-3-carboxamide (20 mg, 0.044 mmol), 1- methylpyrazole-4-boronic acid, pinacol ester (22 mg, 0.1 mmol), 1,1'- bis(diphenylphosphino)ferrocenedichloro palladium(II) (5 mg, 0.0072 mmol), and cesium carbonate (49 mg,
- Example 181 (S)-N-(2-fluoro-5-(2-(3-methoxypyrrolidin-1-yl)acetamido)pyridin-3-yl)-6- (1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- Step a ethyl 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxylate
- ethyl 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxylate To a mixture of ethyl 6-chloropyrazolo[1,5-a]pyrazine-3-carboxylate (3.0 g, 13.3 mmol) in dioxane (60 mL) and H 2 O (15 mL).Then 1-methyl-4-(4,4,5)
- Step b 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxylic acid
- ethyl 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyrazine-3-carboxylate 2.0 g, 7.4 mmol
- lithium hydroxide hydrate 393 mg, 9.4 mmol
- H 2 O 10 mL
- Step d tert-butyl (5-amino-6-fluoropyridin-3-yl)carbamate
- tert-butyl (6-fluoro-5-nitropyridin-3-yl)carbamate 1.3 g, 4.0 mmol
- NH 4 Cl 0.88 g, 16.4 mmol
- Fe 0.91 g, 16.3 mmol
- Step e tert-butyl (6-fluoro-5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3- carboxamido)pyridin-3-yl)carbamate
- 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3- carboxylic acid (4.0 g, 15.8 mmol) and SOCl 2 (55 mL) was added. Then the reaction mixture was stirred at 70°C for 1 hour.
- Step g N-(5-(2-chloroacetamido)-2-fluoropyridin-3-yl)-6-(1-methyl-1H-pyrazol-4- yl)pyrazolo[1,5-a]pyrazine-3-carboxamide
- N-(5-amino-2-fluoropyridin-3-yl)-6-(1-methyl-1H- pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide 400 mg, 0.89 mmol
- DMF 15 mL
- NaHCO 3 237 mg, 2.8 mmol
- 2-chloroacetyl chloride 153 mg, 1.4 mmol
- Step h (S)-N-(2-fluoro-5-(2-(3-methoxypyrrolidin-1-yl)acetamido)pyridin-3-yl)-6-(1- methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide [00889] To the mixture of N-(5-(2-chloroacetamido)-2-fluoropyridin-3-yl)-6-(1- methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carboxamide (200 mg, 0.35 mmol) in DMF (10 mL) was added (S)-3-methoxypyrrolidine (77 mg, 0.76 mmol), K 2 CO 3 (204 mg, 1.5 mmol) and NaI (68 mg, 0.45 mmol).
- Instrumentation a. Compound liquid handling: LabCyte Echo; b. Reagent liquid handling: Thermo Scientific Multidrop Combi; c. BMG PHERAStar multilabel plate reader.
- Protein Reagent His6-TEV-PDGFR ⁇ Protein Prep prepared at Accelagen.
- II. Methods and Procedures [00898] Stock solutions: [00899] Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl 2 , 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in molecular biology grade water. Store at room temperature.
- DTT 2 M in molecular biology grade water, store at -20°C in aliquots.
- Ovalbumin 10% or 100 mg/mL, prepare fresh on experimental day.
- PDGFR ⁇ 116 ⁇ M (PDGFRb_08 Prep 02), produced at Accelagen. Store at -80°C in aliquots.
- TK-biotin peptide 0.5 ⁇ M in molecular biology grade water, store at - 20°C in aliquots.
- ATP 100 mM in molecular biology grade water, store at -20°C in aliquots.
- HTRF KinEASE-TK kit Allow the contents of the Cisbio kit to warm up to room temperature before use. This kit contains HTRF detection buffer, TK-Antibody labeled with Eu 3+- cryptate, TK-substrate biotin and Streptavidin-XL665. [00906] TK Substrate-Biotin, reconstitute 500 ⁇ g lyopholized with 574 ⁇ L molecular biology grade water to prepare a 500 ⁇ M stock; After use, aliquot the rest and store at -20°C.
- TK Antibody-Cryptate reconstitute lyophilized with 1 mL of molecular biology grade water (100x solution) then add 99 mL detection buffer to prepare a ready to use TK-antibody-cryptate solution; the concentration of the TK-antibody-cryptate reagent is not known. After use, aliquot the rest and store at -20°C.
- Freshly prepared solutions [00910] Assay buffer. Dilute 5x Kinase buffer 5-fold with molecular biology grade water and add DTT to 2 mM and ovalbumin to 0.1 mg/mL (or 0.01%). [00911] 2X protein solution. Make a working solution of 100 pM PDGFR ⁇ in assay buffer. Keep on ice until use to maintain enzyme stability. [00912] 2X substrate solution. Make a working solution of 1.6 mM ATP and 1 ⁇ M TK-substrate biotin peptide in assay buffer. [00913] 3X quench/detection solution.
- Assay Procedure [00921] Assay in white ProxiPlate 384-well [00922] Step 1. Dispensing inhibitors/DMSO and low control: Using the ECHO 555 acoustic dispenser, spot desired compound serial dilutions in DMSO, NEAT DMSO to represent the uninhibited enzyme control, and 10 ⁇ M final [imatinib] to the represent the 100% inhibited enzyme control [00923] Step 2. PDGFR ⁇ E + I pre-incubation: Add 2 ⁇ L 2x protein solution to columns 1-24 using the Multidrop Combi. Centrifuge at 1000 rpm for 1 min. Incubate 30 min at RT [00924] Step 2.
- Enzymatic reaction Add 2 ⁇ L substrate solution to columns 1-24 to initiate the reaction using the Multidrop Combi; cover/seal the assay plate to reduce evaporation. Centrifuge at 1000 rpm for 1 min. Incubate at room temperature for 3 hours.
- HTRF ratio values calculated by the instrument (Ratio is acceptor counts/donor counts * 10,000) is exported from the plate reader and used in data analysis. The exported data will be used to calculate 1) compound activity and 2) assay statistics.
- Compound activity is represented by % Inhibition when testing a single dose of a compound or IC50 when testing a dose response of a compound.
- Assay statistics can include Robust Z’ and Signal to Background.
- PDGFR ⁇ LanthaScreen assay [00951] I. Materials [00952] II. Methods and Procedures [00953] Stock solutions: [00954] Assay buffer stock contains 50 mM HEPES pH7.5, 10 mM MgCl 2 , 0.01% Brij- 35, 1 mM EGTA. [00955] Tb-labeled inactive PDGFR ⁇ .3.6 ⁇ M in 50 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% Tween-20 and 10% glycerol. Store at -80 o C in aliquots. [00956] Tracer 222, 50 ⁇ M in DMSO, store at -20 o C.
- Freshly prepared solutions [00958] Assay buffer. Add DTT to 2 mM and ovalbumin to 0.1 mg/mL to Assay buffer stock. [00959] Kinase-Tracer solution. Make a working solution of 0.2 nM Tb-labeled inactive PDGFR ⁇ and 40 nM Tracer 222 in Assay buffer. Keep on ice until use. [00960] Assay Procedure: [00961] Step 1. Dispensing inhibitors: Using Echo, dispense 40nL/well (or less) compound serial dilutions in DMSO onto the assay plate. [00962] Step 2. Dispensing Kinase-Tracer solution: Add 4 ⁇ L/well Kinase-Tracer solution.
- % Inhibition (NC – sample) / (NC – PC) * 100 where NC is the mean of negative control (reactions without inhibitor), and PC is the mean of positive control (1 ⁇ M sunitinib).
- PDGFR ⁇ cellular assay [00972] I. Materials [00973] II. Methods and Procedures [00974] Cell Culture and Preparation: Cells are cultured according to ATCC procedure (5) with the addition of the antibiotic penicillin-streptomycin. If working from frozen, cells should be thawed according to ATCC procedure. Depending on the cell density of frozen vial, cells will need time to recover from thaw. An 80% confluent T75 flask should be enough for one 384 well plate. [00975] Stock Solutions: Rat PDGFBB. A 100ug/mL stock is prepared by reconstituting 50ug in 500uL of 4mM HCl and 0.1% BSA.
- Freshly Prepared Solutions [00977] 1x Cisbio cell lysis buffer. The cell lysis buffer is diluted 4-fold with molecular grade water. The blocking agent is then diluted 25-fold in the diluted lysis buffer. [00978] Antibody solutions. Equal amounts d2 and cryptate antibody are diluted 20-fold in detection buffer. [00979] Rat PDGFBB. A working stock of 100ng/mL is created from the stock solution in 10%FBS culture media.
- Step 1 Plating Cells: Media from the A10 cell flask is aspirated. The cells are rinsed with PBS and then trypsinized to disperse the cell layer. The cells are then pelleted are resuspended to 1.25e5 cells/mL. 40uL of cells are then plated in 384 Greiner TC treated plates at a density of 5000 cells/well using the Combi. Plates are covered and placed in the incubator (37°C 5% CO2) overnight to allow cells to adhere.
- Step 2 Compound Dispense: Approximately 18 hours after plating, dispense 40nL compound onto cells using Echo.
- Step 3 Activation by PDGFbb: 6uL of the working stock of 100ng/mL PDGFbb is dispensed using the Tempest to give a final assay concentration of 15ng/mL (EC80). After 10 minutes the media is removed by flicking the plate.
- Step 4 Cell lysis and antibody addition: 20uL lysis buffer per well is added to the plate via Tempest. 5uL antibody solution is added per well via the Tempest. The plate is placed on the shaker at 230 rpm for 1 hour at room temperature.
- Assay buffer stock contains 50mM HEPES pH7.5, 10mM MgCl2, 0.01% Brij-35, and 1mM EGTA.
- 10mg/mL srctide solution prepared in Assay buffer (Assay buffer stock with 2mM DTT, 0.1% Pluronic F-127, and 0.1mg/mL ovalbumin).
- Step 2 Pre-incubation of inhibitors with kinase: Add 2 ⁇ L/well 2X kinase solution. Centrifuge at 1000 rpm for 1 min. Incubate at room temperature for 30 min.
- Step 3 Kinase cascade reaction: Add 2 ⁇ L/well 2X substrate/ATP solution to initiate kinase reactions.
- % Inhibition (NC – sample) / (NC – PC) * 100 where NC is the mean of negative control (reactions without inhibitor), and PC is the mean of positive control (1 ⁇ M TAK-593).
- IC50 determination Compounds are serially diluted 3-fold and tested in an 11- point dose response.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci. L'invention concerne également des compositions pharmaceutiques comprenant des composés de formule (I), ainsi que leurs procédés d'utilisation et de préparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263354276P | 2022-06-22 | 2022-06-22 | |
US63/354,276 | 2022-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023247595A1 true WO2023247595A1 (fr) | 2023-12-28 |
Family
ID=87003229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/066732 WO2023247595A1 (fr) | 2022-06-22 | 2023-06-21 | Pyrazolopyrazine carboxamides et leurs utilisations comme inhibiteurs de pdgfr |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023247595A1 (fr) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4739762A (en) | 1985-11-07 | 1988-04-26 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US5195984A (en) | 1988-10-04 | 1993-03-23 | Expandable Grafts Partnership | Expandable intraluminal graft |
US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
US5451233A (en) | 1986-04-15 | 1995-09-19 | Yock; Paul G. | Angioplasty apparatus facilitating rapid exchanges |
US5496346A (en) | 1987-01-06 | 1996-03-05 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
WO2013030802A1 (fr) | 2011-09-01 | 2013-03-07 | Novartis Ag | Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire |
-
2023
- 2023-06-21 WO PCT/EP2023/066732 patent/WO2023247595A1/fr unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4739762A (en) | 1985-11-07 | 1988-04-26 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4739762B1 (en) | 1985-11-07 | 1998-10-27 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5451233A (en) | 1986-04-15 | 1995-09-19 | Yock; Paul G. | Angioplasty apparatus facilitating rapid exchanges |
US5496346A (en) | 1987-01-06 | 1996-03-05 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5195984A (en) | 1988-10-04 | 1993-03-23 | Expandable Grafts Partnership | Expandable intraluminal graft |
US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US5879382A (en) | 1989-08-24 | 1999-03-09 | Boneau; Michael D. | Endovascular support device and method |
US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
WO2013030802A1 (fr) | 2011-09-01 | 2013-03-07 | Novartis Ag | Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire |
Non-Patent Citations (7)
Title |
---|
"Basic and Clinical Pharmacology", 2003, MCGRAW HILL |
"Handbook of Clinical Drug Data", 2002, MCGRAW-HILL |
"Martindale, The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS |
"Principles of Drug Action", 1990 |
"Remingtons Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS |
"The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL |
SHAW DUNCAN E. ET AL: "Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 17, 19 August 2016 (2016-08-19), US, pages 7901 - 7914, XP093069286, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b00703 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020202707B2 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity | |
US10787452B2 (en) | Compounds useful as inhibitors of ATR kinase | |
AU2023233205A1 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
TWI503322B (zh) | 作為cdk4/6抑制劑之吡咯并嘧啶化合物 | |
RU2638116C2 (ru) | Пиразоло[3,4-с]пиридины и способы их применения | |
AU2022209304A1 (en) | Heteroaryl compounds for treating Huntington's disease | |
CA3139821A1 (fr) | Composes pour le traitement de la maladie de huntington | |
KR20150028999A (ko) | 5-아자인다졸 화합물 및 이의 사용 방법 | |
JP2021506941A (ja) | ジアザインドール化合物 | |
EP4267585A1 (fr) | Pyrazolothiazole carboxamides et leurs utilisations en tant qu'inhibiteurs de pdgfr | |
TW202104230A (zh) | 用於治療自體免疫疾病之六氫-1H-吡并[1,2-a]吡化合物 | |
WO2022207924A1 (fr) | Dérivés de (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[pipéridine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine et composés similaires servant d'inhibiteurs de shp2 pour le traitement, par exemple, du cancer | |
WO2023091726A1 (fr) | Inhibiteurs de la kinase 12 dépendante de la cycline (cdk12) | |
CN118556059A (zh) | 用于治疗癌症的杂环化合物 | |
WO2023247595A1 (fr) | Pyrazolopyrazine carboxamides et leurs utilisations comme inhibiteurs de pdgfr | |
WO2023247593A1 (fr) | Pyrrolopyridine carboxamides et leurs utilisations en tant qu'inhibiteurs de pdgfr | |
WO2023247590A1 (fr) | Carboxamides de triazolopyridine et de benzoisoxazole et leurs utilisations en tant qu'inhibiteurs de pdgfr | |
WO2023247596A1 (fr) | Pyrazolothiazole carboxamides et leurs utilisations comme inhibiteurs de pdgfr | |
AU2022317287A1 (en) | Pyrazolopyrimidines and their uses as pdgfr inhibitors | |
WO2024104968A1 (fr) | Pyrazolopyrrolopyridazines et leurs utilisations en tant qu'inhibiteurs de pdgfr | |
CN116802184A (zh) | 吡唑并噻唑甲酰胺及其作为pdgfr抑制剂的用途 | |
TW202342483A (zh) | 治療自體免疫疾病之咪唑大環 | |
WO2024091370A1 (fr) | Composés hétéroaromatiques bicycliques fusionnés en 5,6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23734942 Country of ref document: EP Kind code of ref document: A1 |